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Abstract 
 
It is well-established that transient activation of the β-adrenergic signalling pathway with ligands such 
as isoproterenol, formoterol and dobutamine, elicits cardioprotection against subsequent long 
periods of ischaemia. Initially the focus was on the β1- and β2-adrenergic receptors (β1-AR, β2-AR), 
but recently the β3-AR also emerged as a potential target in the treatment of heart disease. In heart 
failure, β1- and β2-AR are typically known to be down-regulated while β3-ARs, on the other hand, are 
up-regulated (Moniotte et al., 2001).  Thus, it has become important to examine the significance of 
the β3-AR and its downstream signalling under similar states of stress. It has been shown that β3-AR 
stimulation is resistant to short term agonist-promoted desensitization in vitro and in vivo (Liggett et 
al., 1993) and after being activated, this receptor is able to convey continual intracellular signals 
(Lafontan et al., 1994). Thus, it could be an ideal target for therapeutic intervention, also in ischaemic 
heart disease. We hypothesized that selective β3-AR stimulation during ischaemia / reperfusion may 
be cardioprotective, whereas selective inhibition of this receptor may prove useful in the end stages 
of sustained ischaemia and early reperfusion. Methods:  The isolated working rat heart, subjected to 
35 min of regional ischaemia (RI) and 60 min reperfusion was used as model. The β3-AR agonist 
(BRL37344) (1 µM) or antagonist (SR59230A) (0.1 µM) were applied as follows: (i) before 35 min RI 
(PT), (ii) during the last 10 min of RI (PerT) and /or (iii) at the onset of reperfusion (PostT) and (iv) 
administration of BRL37344 during the last 10 min of RI BRL37344 (PerT) was followed by SR59230A 
during first 10 min of reperfusion SR59230A (Post). The contribution of nitric oxide synthase (NOS) in 
β3-AR was assessed, using the non-specific NOS inhibitor, L-NAME (50 μM). Endpoints were 
functional recovery and infarct size. In another set of experiments BRL37344 and SR59230A were 
applied according to the same protocols, but the left ventricle was dissected from the heart and 
freeze clamped at 10 min reperfusion for Western blot analysis of extracellular signal-regulated 
kinase (ERK p44/p42), protein kinase B (PKB/Akt), glycogen synthase kinase-3β (GSK-3β), and 
endothelial nitric oxide synthase (eNOS). Data were analyzed with one or two-way analysis of 
variance (ANOVA). Results: Administration of the selective β3-AR agonist (BRL37344) (1µM) before 
35 min RI (BRL37344 (PT), significantly reduced infarct size when compared to the non-pretreatment 
group (NPT) (21.43±2.52 vs 43.17±1.20, p < 0.001). BRL37344 had similar effects on infarct size when 
Stellenbosch University  https://scholar.sun.ac.za
iv 
 
applied during the last 10 min of regional ischaemia BRL37344 (PerT) (14.94±2.34, vs NPT, p < 0.001) 
or at the onset of reperfusion BRL37344 (PostT) (19.06±1.81, vs NPT, p < 0.001). When BRL37344 was 
applied as a (PerT+PostT) strategy, infarct size was once again significantly reduced (20.55±2.01 vs 
43.17±1.20, p <0.001). In contrast, administration of the β3-antagonist SR59230A according to the 
same protocol did not reduce infarct size and values similar to those of untreated hearts (NPT) were 
obtained. Surprisingly, when BRL37344 was applied during the last 10 min of regional ischaemia 
followed by the administration of the β3-AR antagonist (SR59230A) at the onset of reperfusion, 
[BRL37344 (PerT) & SR59230A (PostT)], infarct size was significantly reduced to 20.78±3.02 (p <0.001 
vs NPT and SR59230A (PerT + PostT). Involvement of nitric oxide (NO) was shown since the reduction 
in infarct size elicited by BRL37344 was totally abolished by, L-NAME, when administered in 
combination with BRL37344 for 10 minutes prior to RI or at the onset of reperfusion for 10 minutes 
(% infarct size: 41.48±3.18 and 35.75±3.54, p <0.001 vs BRL37344 (PT) and BRL37344 (PostT), 
respectively. Western blot results show that PKB/Akt is activated by BRL37344 regardless of the time 
of administration. The intervention BRL37344 (PerT+PostT), exhibited the most significant 
phosphorylation of PKB/Akt (fold increase: 14.2±3.71, p<0.01 vs NPT and p<0.05 vs BRL37344 
(PostT). In addition, BRL37344 (PT), (PerT), (PostT) and [BRL37344 (PerT) +SR59230A (PostT)] 
showed significant activation of this kinase (2.92±0.22, 5.54±0.43, 4.73±0.47, and 6.60±0.78, 
respectively). ERKp44/p42 however, was not significantly activated by any of the treatments. 
Phosphorylation of eNOS and GSK-3β was significant only in the BRL37344 (PerT+PostT) and 
[BRL37344 (PerT) + SR59230A (PostT)] groups. The activation of eNOS-S-1177 in the BRL37344 
(PerT+PostT) group was (2.82±0.46, p<0.01 and 0.05 vs NPT and BRL37344 (PostT), respectively) and 
in the [BRL37344 (PerT) + SR59230A (PostT)] group was (2.26±0.48, p<0.05 vs NPT). A very significant 
increased phosphorylation of GSK-3β was seen in the same two groups (68.8±7.73, p<0.001 vs NPT 
and 25.5±5.42 vs NPT, p<0.05, respectively). Conclusion: β3-AR has potent cardioprotective effects 
when administered either before, during and after ischaemia during early reperfusion as indicated by 
the reduction in infarct size as well as activation of PKB, GSK-3β and eNOS.  These beneficial effects 
can be linked to NO production through activation of eNOS. 
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Abstrak 
 
Dit is bekend dat verbygaande aktivering van die β-adrenerge seinpad, met ligande soos 
isoproterenol, formoterol en dobutamien, die hart teen daaropvolgende lang periodes van iskemie 
beskerm.  Aanvanklik was die fokus op die β1- en β2-adrenerge reseptore (β1-AR, β2-AR); maar 
onlangs is ook die β3-AR as 'n potensiële teiken in die behandeling van hartsiektes ge-eien. In 
hartversaking, is dit bekend dat β1- en β2-AR afreguleer word, terwyl β3-ARs, aan die ander kant, 
opreguleer word (Moniotte et al., 2001).  Dit het dus belangrik geword om die belang van die β3-AR 
en sy stroomaf seinpad onder soortgelyke strestoestande te ondersoek. Dit is bewys dat β3-AR 
stimulasie teen korttermyn agonis geïnduseerde desensitisering in vitro en in vivo bestand is (Liggett 
et al., 1993) en wanneer geaktiveer, is hierdie reseptor in staat om intrasellulêre seine voortdurend 
oor te dra (Granneman, 1995). Dit kan dus ‘n ideale teiken vir terapeutiese intervensie wees, ook in 
iskemiese hartsiekte. Ons hipotetiseer dat selektiewe β3-AR stimulasie tydens iskemie / reperfusie 
kardiobeskermende mag wees, terwyl selektiewe inhibisie van hierdie reseptor effektief kan wees in 
die eindstadia van volgehoue iskemie en vroeë herperfusie. Metodes: Die geïsoleerde werkende 
rothart, onderwerp aan 35 min van streeksiskemie (SI) en 60 min herperfusie, is as model gebruik. 
Die β3-AR agonis (BRL37344) (1μM) of antagonis (SR59230A) (0.1 μM), is as volg toegedien: (i) voor 
35 min SI (PT), (ii) gedurende die laaste 10 min van SI (PerT) en / of (iii) tydens die aanvang van 
herperfusie (PostT) en (iv) gedurende die laaste 10 min van SI is BRL toediening BRL37344 (PerT) 
gevolg deur SR59230A tydens die eerste 10 min van herperfusie SR59230A (Post). Die rol van 
stikstofoksiedsintase (NOS) in β3-AR is met behulp van die nie-spesifieke NOS inhibitor, L-NAME (50 
μM) ondersoek. Eindpunte was funksionele herstel tydens herperfusie en infarktgrootte. In 'n ander 
reeks eksperimente is BRL37344 en SR59230A volgens dieselfde protokolle toegedien, maar die linker 
ventrikel is uit die hart gedissekteer na 10 min herperfusie en gevriesklamp vir Western klad analise 
van ekstrasellulêre-sein gereguleerde kinase (ERK p44/p42), proteïen kinase B (PKB/Akt), glikogeen 
sintase kinase-3β (GSK-3β), en endoteel stikstofoksied- sintase (eNOS). Data is met een of twee-
rigting variansie analise (ANOVA) ontleed.  Resultate: Administrasie van die selektiewe β3-AR agonis 
(BRL37344) (1μM) voor 35 min SI BRL37344 (PT), het die infarktgrootte beduidend verminder 
vergeleke met die nie-behandelde groep (NPT) (21.43±2.52 vs 43.17±1.20, p<0.001). BRL37344 het ‘n 
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soortgelyke effek op infarktgrootte wanneer dit gedurende die laaste 10 min van streeksiskemie 
BRL37344 (PerT) (14.94±2.34, vs NPT, p<0.001) of by die aanvang van herperfusie (BRL37344 (PostT) 
(19.06±1.81, vs NPT, p<0.001) toegedien word. Wanneer BRL37344 as 'n (PerT+PostT) strategie 
toegedien is, was infarktgrootte weereens beduidend verlaag (20.55±2.01 vs 43.17±1.20, p<0.001). In 
teenstelling hiermee, het administrasie van die β3-antagonis SR59230A volgens dieselfde protokol, 
nie infarktgrootte verminder nie en waardes soortgelyk aan dié van onbehandelde harte (NPT) is 
verkry. Interessant, wanneer BRL37344 gedurende die laaste 10 min van streeksiskemie toegedien is, 
gevolg deur die administrasie van die β3-AR antagonis (SR59230A) by die aanvang van herperfusie, 
[BRL37344(PerT) & SR59230A(PostT)], was infarktgrootte aansienlik verminder tot 20.78±3.02 
(p<0.001 vs NPT en SR59230A (PerT+PostT). Die betrokkenheid van stikstofoksied (NO) is  
waargeneem deurdat die vermindering in infarktgrootte ontlok deur BRL37344, heeltemal deur L-
NAME opgehef is, wanneer dit in kombinasie met BRL37344 vir 10 minute voor SI of by die aanvang 
van herperfusie vir 10 minute toegedien is (% infarktgrootte: 41.48±3.18 en 35.75±3.54, p<0.001 vs 
BRL37344 (PT) en BRL37344 (PostT) onderskeidelik). Western kladresultate toon dat PKB/Akt deur 
BRL37344 geaktiveer word ongeag die tyd van die administrasie. Die intervensie BRL37344 
(PerT+PostT), toon die mees beduidende fosforilering van PKB/Akt (voudige toename: 14.2±3.71, 
p<0.01 vs NPT en p<0.05 vs BRL37344 (PostT). Daarbenewens het BRL37344 (PT), (PerT), (PostT) en 
[BRL37344 (PerT) + SR59230A (PostT)] ook beduidende aktivering van hierdie kinase tot gevolg 
gehad (2.92±0.22, 5.54±0.43, 4.73±0.47 en 6.60±0.78, onderskeidelik). ERKp44/p42 is egter nie deur 
enige van die behandelings geaktiveer nie.  Fosforilering van eNOS en GSK-3β was net beduidend in 
die BRL37344 (PerT+PostT) en [BRL37344 (PerT) + SR59230A (PostT)] groepe. Die aktivering van 
eNOS-S-1177 was beduidend in die BRL37344 (PerT+PostT) en [BRL37344 (PerT) + SR59230A (PostT)] 
groepe. 'n Baie beduidende toename in fosforilering van GSK-3β is in dieselfde twee groepe 
(68.8±7.73, p<0.001 en 25.5±5.42, p<0.05 vs NPT onderskeidelik) waargeneem.  Gevolgtrekking: β3-
AR het kragtige kardiobeskermende effekte wanneer dit, hetsy voor, tydens en na iskemie gedurende 
vroeë herperfusie toegedien word, soos deur die vermindering in infarktgrootte sowel as die 
aktivering van PKB, GSK-3β en eNOS aangedui is. Hierdie voordelige effekte kan aan NO produksie 
deur aktivering van eNOS gekoppel word. 
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Chapter 1 
 
Introduction 
Ischaemic heart disease (IHD) remains a leading cause of mortality and morbidity world-wide, and 
approximately more than 3 million men and women die of the disease annually (Murray and 
Lopez, 1997). In acute coronary syndrome (ACS), such as acute myocardial infarction (AMI), the 
coronary artery or one of its smaller branches is totally occluded by small migrated emboli from 
plaque rupture site while in chronic IHD, such as stable angina pectoris, the coronary artery is 
partially occluded by a previously formed intracoronary atherosclerotic plaque (Agewall S., 2008). 
Although the pathophysiological background for both conditions are similar, chronic IHD have 
better prognosis than ACS (Agewall S., 2008). Therefore, more studies about myocardial 
protection should be focused on utilizing pathophysiological models of AMI. 
Following coronary occlusion, deprivation of oxygen and nutrient metabolites is the primary cause 
of damage to the myocardium. It is well-established that myocardial ischaemia results in 
numerous intracellular changes for example loss of ATP, a fall in pH, accumulation of lactate, 
oxidative stress, inorganic phosphate and calcium overload (for a review see Ong et al., 2015). 
Survival of the ischaemic myocardium is determined by the severity and duration of ischaemia. 
Many of these changes can be remedied by early reperfusion. However, it has become clear that 
reperfusion, although essential for reversal of the ischaemic damage, can also induce additional 
myocardial injury, a phenomenon called reperfusion injury. Reperfusion injury characteristically 
includes myocardial stunning, no-reflow phenomena, reperfusion arrhythmias and cell death 
(Hausenloy et al., 2007). Myocardial stunning is a condition when a portion of the myocardium, 
corresponding to the zone of a major coronary occlusion, contracts abnormally. This might be 
continuing for a period of time and is caused by reactive oxygen species (ROS) production and 
calcium Ca2+ accumulation (Bolli and Marban, 1999). Clinically, it does not appear to be a serious 
condition and disappears spontaneously. Similarly, reperfusion arrhythmias although it is 
potentially harmful, it can be treated easily using alpha blockers, high potassium, high magnesium, 
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calcium antagonists and free radical scavengers (Manning and Hearse, 1984, Yellon and 
Hausenloy, 2007). The no-reflow phenomenon occurs when the myocardial ischaemic area fails to 
be reperfused after reopening the previously occluded coronary artery, due to the resistance of 
microvascular blood flow, resulting from endothelial swelling, cardiomyocyte oedema and 
neutrophil infiltration (Ito et al., 2006, Krug et al., 1966). 
It is well-established that the cell death due to ischaemia/ reperfusion injury (IRI) is caused 
primarily by both necrosis and apoptosis. Necrosis refers to cell death by swelling (oncosis), 
hypercontracture, due to calcium overload, ATP depletion and subsequent membrane rupture. 
The dead cells attract inflammatory cells including macrophages and fibroblasts with subsequent 
scar formation. Apoptotic cell death on the other hand, refers to cell shrinkage and accompanying 
biochemical degradation of intracellular contents with preservation of the cell membrane. This is 
followed by the separation of the nucleus into small portions, which will be engulfed by 
phagocytes (phagocytosis). This process is not associated with fibrosis and scar formation as in 
necrotic cell death, the apoptotic parts are cleared by the adjacent cells, leaving no trace behind 
(Opie L.H., 2004). 
Although irreversible ischaemic damage is a consequence of either apoptosis or necrosis, it is still 
open to debate as to what specific mechanisms are involved by which reversible ischaemic 
damage regresses into irreversible damage. It is known that the development of such damage in 
the necrotic area causes loss of considerable amounts of ATP, sarcolemmal damage, release of 
free radicals, calcium overload, and sodium pump inhibition. However, although reperfusion injury 
could lead to cell death, early reperfusion has become obligatory for all conditioning strategies 
aimed at reduction of infarct size (Ovize et al., 2010). This allows an opportunity to intervene with 
cardioprotective strategies during reperfusion to delay the expected injury. For this reason intense 
research into the development of novel maneuvers and drugs that will limit infarct size is required. 
Consequently, cardioprotection should be aimed at attenuation of the dangerous effects of 
myocardial (IRI), thereby reducing mortality and morbidity in patients with IHD. 
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Numerous researches examined the ability of different strategies to reduce infarct size and 
improve functional recovery of the heart during reperfusion, some of which include mechanical 
interventions such as ischaemic preconditioning (IPC) (Murry et al., 1986), and ischaemic 
postconditioning (IPostC) (Cour et al., 2010), while others include pharmacological interventions 
using pharmacological agents such as calcium channel blockers (Vander Heide et al., 1994), 
adenosine (Liu et al., 1991), alpha1-adrenergic agonists (Bankwala et al.,1994), and beta-
adrenergic antagonists and agonists (Zhang et al.,2010; Salie et al.,2011;2012). 
Subsequently, a major number of drugs have been illustrated to be cardioprotective if 
administered at the time of reperfusion, e.g. activators of kinases (Hausenloy et al, 2004), 
inhibitors of protein kinase C (PKC-δ) (Inagaki et al., 2003), inhibitors of opening the mitochondrial 
permeability transition pore (MPTP) (Hausenloy et al., 2014) (see the review of Ong et al., 2014) 
and inhibition of glycogen synthase kinase-3β (GSK-3β) (Gross et al., 2004). However, until 
recently, translation of these laboratory trials into a successful clinical therapy to the pateints 
presented with IHD, has been largely disappointing (Sharma et a.l, 2012; Heusch et al., 2013; 
Perricone and Vander Heide, 2014). 
Conditioning is a term that has been used to describe a series of short cycles of non-lethal 
ischaemia interrupted by short cycles of reperfusion applied during ischaemia/reperfusion 
protocol. Over the past three decades, researchers have designed several strategies to minimise 
IRI. Depending on the timing of conditioning stimulus application and the windows of therapeutic 
opportunity, conditioning strategies have been classified into three interventions. In ischaemic 
preconditioning (IPC), the conditioning stimulus is applied before the subsequent sustained 
ischaemia, while in ischaemic perconditioning (IPerC) and postconditioning (IPostC), the stimulus 
is applied during and after the major ischaemic event, respectively (Vinten-Johansen and Shi, 
2011). Furthermore, remote ischemic conditioning (RIC) is another cardioprotective strategy in 
which the conditioning stimulus applied to an organ or tissue distant from the heart (Zhu et al., 
2013; Vinten-Johansen and Shi, 2011). In addition, pharmacological conditioning is achieved by 
application of pharmacological agents to protect the heart against IRI (Hausenloy and Yellon, 
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2008).  Elucidation of the mechanisms involved in these strategies may lead to the development of 
new drugs to elicit cardioprotection. 
 
1.1 Ischaemic preconditioning (IPC) 
It was demonstrated that exposure of the heart to short periods of ischaemia/reperfusion, 
significantly protects the heart against a following prolonged period of ischaemia, phenomena 
called ischaemic preconditioning (IPC) (Murry et al., 1986). This phenomenon has been 
investigated in several mammalian species, including sheep, monkeys, rabbits, rats, pigs and dogs 
and it has been illustrated to improve the cardiac contractility during reperfusion (Murry et al., 
1990). Furthermore, IPC was shown to attenuate reperfusion arrhythmias and limit infarct size 
extention (Shiki and Hearse, 1987). Consequently, it has been recognized as the most effective 
cardioprotective intervention for many years (Yellon and Downey, 2003) (for a review see Zhu et 
al., 2013). It has been shown that IPC has two distinct stages of protection. The first stage, termed 
classical/early preconditioning, is elicited within minutes and lasts for 2-3 hours (Murray et al., 
1986) and the second stage is called the second window of protection (SWOP) /delayed or late 
preconditioning, which develops within 12-24h and lasts for 2-3 days (Marber et al., 1993; Kuzuya 
et al., 1993) (for a review see Heusch et al., 2015). It has been shown that IPC successfully 
translated clinically to human. However, it is limited to elective clinical settings such as 
percutaneous coronary intervention (PCI) and coronary bypass grafting, but not in patients 
presenting with acute myocardial infarction (AMI) (Heusch et al., 2013). This has led to intensive 
research to develope new strategies which could be used in patients with AMI. 
1.2 Ischaemic postconditioning (IPostC) 
A large number of studies have established the ability of cardioprotective strategies, administered 
at the onset of reperfusion to reduce infarct size. Vinten-Johansen and colleagues, first noted that 
interrupting myocardial reperfusion with three cycles of 30 seconds coronary artery re-occlusions 
had significant beneficial effects including a reduction in infarct size, less myocardial oedema, 
reduced necrotic and apoptotic cell death and improved endothelial function (Zhao et al., 2003) 
and termed this ischaemic postconditioning (IPostC). Theoretically, this intervention should be 
clinically applicable since it is performed immediately at the beginning of reperfusion. 
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Subsequently, IPostC was used in patients with AMI undergoing PCI, and resulted in a reduction of 
myocardial infarct size by 36% and improved myocardial reperfusion (Staat et al., 2005). The 
mechanism of IPostC induced cardioprotection is not yet fully understood. However, emerging 
evidence suggests that IPC and IPostC have, at least in part, similar signalling pathways at the time 
of reperfusion. These include cell membrane receptors, protein kinase cascades such as the 
Reperfusion Injury Salvage Kinases (RISK) pathway as well as the Survival Activation Factor 
Enhancement (SAFE) pathway, redox signalling, and the MPTP (Hausenloy et al., 2005; Sun et al., 
2005) (discussed later). 
 
1.3 Remote ischaemic conditioning (RIC) 
Remote ischaemic conditioning was initially demonstrated by Przyklenk and colleagues (1993) who 
found that 4 cycles of 5 minutes ischaemia and 5 minutes reperfusion of left circumflex coronary 
artery followed by 60 minutes ischaemia and reperfusion of the left anterior descending (LAD) 
coronary artery, resulted in a reduction in infarct size. Subsequently, myocardial protection was 
elicited by short ischaemia/reperfusion episodes in some organs distant from the heart such as 
brain, intestine, kidney, and skeletal muscle (Przyklenk et al., 2003). Afterwards it was illustrated 
that a brief renal ischaemia/reperfusion at the end of sustained myocardial ishaemia significantly 
reduced infarct size (Kerendi et al., 2005).  This phenomenon which is termed remote ischaemic 
preconditioning (RIPC) might replace invasive interventions such as IPC and IpostC which have to 
be applied to the heart itself to bring about cardioprotection (Zhu et al., 2013). Another study 
using transient limb ischaemia, a more convenient stimulus, applied after myocardial infarction, 
termed remote ischaemic postconditioning (RIPostC), also showed a powerful myocardial 
protection (Andreka et al., 2007). Furthermore, it was demonstrated that transient intermittent 
limb ischaemia in a pig model, applied during the sustained myocardial ischaemia, remote 
ischaemic perconditioning (RPerC), also resulted in a reduction of myocardial infarction and 
improved cardiac function (Schmidt et al., 2007). Subsequently, it was successfully applied 
clinically, by Botker et al and collaborators (2010) who reported that remote perconditioning 
induced by blood pressure cuff inflation on the arms of patients (during the attack of AMI) while 
being transported to the hospital (before application of PCI), resulted in infarct size reduction. 
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Remote conditioning phenomena have been shown to protect other organs as well as the vascular 
system (Heusch et al., 2013; also see the review of Heusch et al., 2015). 
 
1.4 Signalling events of ischaemic conditioning 
Previous studies have investigated the mechanism of IPC-induced cardioprotection to recognize 
the numerous triggers, mediators and effectors which could be involved in this phenomenon (for a 
review see Perricone and Vander Heide, 2014). Triggers are molecules released from some cells 
such as cardiomyocytes, endothelial cells, and leukocytes (Heusch et al., 2012), and stimulated 
during the preconditioning cycles. The cardioprotecton of IPC will be abolished if a trigger is 
inhibited. Triggers include adenosine (Liu et al., 1991; Thoronton et al., 1992), bradykinin (Goto et 
al., 1995), opioids (Genade et al., 2001) and catecholamines (Bankwala et al., 1994).  
Nitric oxide (NO) (Lochner et al; 2002), reactive oxygen species (ROS), for example; ·O2- and H2O2 
and / or reactive nitrogen species (RNS), for example; NO·, Hydrogen Nitrate or Bi Nitrate (HNO) 
and Peroxynitrite anion (ONOO- ), have also been shown to act as triggers but without involvement 
of a receptor (Penna et al., 2009). Mediators are molecules which mediate the mechanisms of 
cardioprotection during the sustained ischaemia as well as at the beginning of reperfusion and 
they are downstream substrates of triggers. Mediators include the mitochondrial KATP channels, 
PKC (Miao et al., 2011) and PKA (Lochner et al., 1999) among others. Similarly, inhibition of these 
mediators leads to attenuation of IPC cardioprotection. Effectors are subcellular molecules or 
organelles which have an important role in salvaging the endangered cardiomyocytes and 
preventing them from cell death. Mitochondria are potential effectors and essential organelles in 
the cell signalling pathway (Heusch et al., 2008). Furthermore, attenuation of calcium 
accumulation and inhibition of proteases (Heusch et al., 2012) are also suggested to be effectors 
of cardioprotection. 
1.4.1 Signalling during reperfusion: RISK and SAFE pathways 
It is well-known that the cardioprotection of IPC is crucially induced by activation of the 
Reperfusion Injury Salvage Kinase (RISK) and the Survival Activation Factor Enhancement (SAFE) 
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pathways at the onset of myocardial reperfusion (Hausenloy et al., 2004, 2011) and there is 
substantial evidence linking these two pathways to MPTP inhibition (Hausenloy et al., 2005; 2009). 
It was well-established that IPC produce its cardioprotective effects by activation of PI3-K/PKB and 
Mitogen-activated protein kinases /extracellular signal-regulated kinases (MEK1/2ERK1/2) during 
reperfusion (Hausenloy et al., 2005), the so-called RISK pathway. Activation of the RISK pathway, 
through triggering of membrane receptors, by autacoids, has also been suggested to be involved 
in the mechanism of postconditioning (Hausenloy et al., 2005). Stimulation of the receptors of 
endogenous adenosine, bradykinin, and opioid has been illustrated to be able to activate and 
phosphorylate the prosurvival kinases PI3K-Akt and MEK1/2-ERK1/2 in IPostC (Bell and Yellon, 
2003; Penna et al., 2007; Gross et al., 2004). Thus, pharmacological inhibition of either of these 
cascades early in reperfusion abolishes the cardioprotective effects of IPC (Hausenloy et al., 2005) 
as well as IPostC (Tsang et al., 2004). It was therefore concluded that both IPC and IPostC actually 
exert their protection early in reperfusion. 
It has been shown that under certain conditions another signalling pathway, the so-called SAFE 
pathway is activated at the onset of myocardial reperfusion (Hausenloy and Yellon, 2004; 2011). 
This pathway, which includes signal transducer and activator of transcription 3 (STAT-3), tumour 
necrosis factor alpha (TNFα) and its receptor subtype 2, has been shown to be involved in 
cardioprotection elicited by both IPC and IPostC at the time of reperfusion (Deuchar et al., 2007; 
Lecour et al., 2009; Lacerda et al., 2009). Activation of the RISK and SAFE pathways has been 
suggested to converge on the mitochondria and to prevent opening of the MPTP during 
reperfusion, resulting in cardioprotection (Heusch et al., 2015; Boengler et al., 2010). However, 
the exact mechanism still needs to be elucidated. 
Regarding the signalling of RIC phenomena, some researchers have suggested that transmission of 
the cardioprotective signals from the stimulus to the heart is a result of either neuronal or 
hormonal transmission, as the signal might be transmitted by blood  between species (Przyklenk 
et al., 2011) (see a review by Heusch et al., 2013). Local ischemia/reperfusion injury in an organ 
distant from the heart stimulates the sensory fibres in that organ and subsequently activates the 
cardiac innervation via the central nerve system (Heusch et al., 2015). In the heart the 
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cardioprotective signalling of RIC appears to be similar to those elicited by IPC and IPostC, 
especially the involvement of the local triggers such as bradykinin (Jones et al.,2009); opioids 
(Patel et al., 2002) and adenosine (Leung et al., 2014). However, it has been noticed that PKC 
(Jones et al., 2009), the RISK pathway (Hausenloy et al., 2012) and eNOS (Rassaf et al., 2014) play a 
more important role in RIC than in IPC and IPostC (Heusch et al., 2015). Furthermore, 
mitochondria (Tsang et al., 2004) and the KATP channels (Schmidt et al., 2007) are also involved as 
effectors in RIC. 
 
1.4.2 The mitochondrial permeability transition pore (MPTP) and cardioprotection 
The MPTP, a non-selective channel of the inner mitochondrial membrane (Griffiths et al., 1995), 
has been demonstrated to be a critical determinant of cardiomyocyte death. It was illustrated that 
this channel remains closed during prolonged ischaemia and only starts opening during the first 
few minutes of reperfusion (Griffiths and Halestrap, 1995; Halestrap and Richardson, 2014). 
Interestingly, it has been found that lactate accumulation during ischaemia produced a powerful 
inhibitory effect on the MPTP (Bernardi et al., 1992, see a review Ong et al., 2015). On the other 
hand, rapid correction of physiological pH during the first few minutes of reperfusion, due to 
washout of lactic acid as well as stimulation of the Na+–H+ and Na+–HCO3 transporters, causes the 
MPTP to open at this time. MPTP opening collapses the mitochondrial membrane potential and 
uncouples oxidative phosphorylation that result in ATP depletion. In addition, the outer 
mitochondrial membrane rupture and subsequent release of cytochrome C which stimulate 
apoptosis and the proteolytic processes that lead to cell death. This has been confirmed by a 
number of researchers using different methods (Di Lisa et al., 2001; Murata et al., 2001; 
Matsumoto-Ida et al., 2006; Heusch et al., 2010). 
Inhibition of MPTP during reperfusion is the main aim for all cardioprotective manoeuvres to 
harness IRI. Although the exact mechanism by which the RISK and SAFE pathways inhibits the 
MPTP is unclear, it has been suggested to produce this effect via phosphorylation of downstream 
targets of PKB/Akt and ERKp44/p42 such as PKG, GSK-3β (for a review see Ong et al., 2014) and 
PKCε (Hausenloy et al., 2005). 
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1.5 The contribution of PKB/Akt, glycogen synthase3-β and the mitogen activated protein 
kinases (MAPK) in cardioprotection 
 
1.5.1 PI-3K and PKB/Akt and cardioprotection:  
Phosphoinositide 3-kinase (PI-3K) is a group of enzymes which act as lipid and protein kinases. 
Based on the specificity of their downstream substrate, mode of action and molecular structure, 
they have been classified into three classes (I, II, and III) (Oudit et al., 2004). Class I PI3-K has been 
subdivided into two subclasses, Class IA PI3-K and Class IB PI3-K, both of which are expressed in 
cardiomyocytes. Class IA PI3-K are heterodimers of a 110-kDa catalytic subunit (p110α, p110β, 
p110δ) and a regulatory subunit of 85 or 55 kDa (p85/p55). Class IB PI3-K consists of a 110ץ 
catalytic subunit and a p101 regulatory subunit (Naga Prasad et al., 2002). Class IA PI3-Ks are 
activated in response to receptor tyrosine kinase pathways (Luo et al., 2005), whereas Class IB PI3-
K is coupled to G protein-coupled receptors (GPCR) and has been shown to play an important role 
in the regulation of cardiac contractility (Nienaber et al., 2003). 
It has been recognized that PKB/Akt is activated during ischaemia/reperfusion, and subsequently, 
it was suggested that activation of this kinase could be an important target for cardioprotective 
interventions to attenuate IRI (Matsui et al., 2001). For example, it has been clearly illustrated that 
brief activation of the β-AR with isoproterenol resulted in enhanced tyrosine kinase-associated 
PI3-K activity and phosphorylation of PKB/Akt and p70S6K in cardiomyocytes (Yano et al., 2008). 
Furthermore, PKB/Akt has an important role in manipulation of some processes such as 
hypertrophy and cardiomyocyte apoptosis (Oudit et al., 2004).  
Although it has been shown that acute stimulation of this signalling pathway has beneficial effects, 
prolonged stimulation has potentially harmful effects (Franke et al., 2003). PKB/Akt could be 
dephosphorylated by PTEN (phosphatase and tensin homolog deleted on chromosome ten) (Leslie 
and Downes, 2004), a protein which is responsible for protecting normal cells against chronic 
stimulation of PI3-K/Akt pathway. 
A number of pharmacological agents for example insulin (Jonassen et al., 2001), urocortin (Brar et 
al., 2001), atorvastatin and bradykinin (Bell and Yellon, 2003), have been demonstrated to be 
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involved in the PI3-K/Akt signalling pathway, and they have also been shown to be 
cardioprotective aganist IRI. Subsequently, these observations suggest that pharmacological 
activation of this pro-survival kinase is able to protect the heart from IRI and subsequent cell death 
(Hausenloy and Yellon, 2004). 
Insulin or insulin-like growth factor-1 (IGF-1) signalling is mediated through tyrosine kinase 
phosphorylation of insulin receptor substrate -1 and -2 (IRS-1; IRS-2) which subsequently activate 
PI3-K. Furthermore, the platelet-derived growth factor receptors (PDGFR) and the epidermal 
growth factor receptors (EGFR) are also involved in activation of PI3-K (Kamohara et al., 1995). 
Activated PI3-Ks convert phosphatidylinositide-4,5-biphosphate (PIP2) to phosphatidylinositide-
3,4,5-triphosphate (PIP3), which acts as a second messenger enhancing different downstream 
effectors, such as phosphatidylinositide-dependent kinase-1 (PDK1/2) which subsequently 
activates a variety of kinases including protein kinase B (PKB/Akt) (Burgering and Coffer, 1995). 
The serine / threonine kinase PKB/Akt plays an important role in the modulation of cellular 
growth, survival and metabolism. Its isoforms, Akt1,-2,-3, can be stimulated by activated beta-
adrenergic receptors (β-ARs), adenosine, and a number of hormones and growth factors, including 
insulin, insulin growth factor-1, and VEGF. Activated PKB/Akt may lead to phosphorylation and 
negative regulation of its proapoptotic downstream targets such as glycogen synthase kinas-3-
beta (GSK-3β) (Nishihara et al., 2006), the Bcl-2-associated death promoter (BAD) (Jonassen et al., 
2001), Cysteine-ASPartic acid protease 9 (Caspase 9) and Forkhead box O proteins (FOXOs) ( Yu et 
al., 2015). Furthermore, activated PKB/Akt might also lead to phosphorylation and activation of its 
antiapoptotic targets such as S6 ribosomal protein kinase (p70s6K) (Jonassen et al., 2001) and 
endothelial nitric oxide synthase (eNOS) (Bell and Yellon., 2003;  Yu et al., 2015) which lead to cell 
survival (Fig.1.1). In addition, it is well known that activation of PKB/Akt leads to stimulation of the 
eNOS-NO-cGMP-PKG signalling pathway, which subsequently inhibits MPTP opening (Garlid et al., 
2004) (see a recent review by Heusch et al., 2015).  
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Fig. 1.1 Akt-mediated survival signalling ( Yu et al., 2015) 
 
 
1.5.2 Glycogen synthase kinase-3β (GSK-3β) 
It is well-known that glycogen synthase kinase-3β (GSK-3β) is a downstream target of PI3-K-
PKB/Akt and a host of other kinases (Juhaszova, et al, 2009; Ong et al., 2014) and it was suggested 
that phosphorylation and inhibition of this kinase can be linked to a diversity of cardioprotective 
signalling pathways (Ong et al., 2015). This has been supported by a study where IPC caused an 
increase in GSK-3β phosphorylation, and this increase was blocked by wortmannin, a specific PI3-
kinase inhibitor (Tonget al., 2002). Therefore, GSK-3β has been recognized as an important role 
player in mediating the downstream signalling which converges on the MPTP (Juhaszova et al., 
2004. The convergence of these pathways via inhibition of GSK-3β, on the end effector, MPTP, to 
Stellenbosch University  https://scholar.sun.ac.za
12 
 
limit permeability transition, is currently regarded as the general mechanism of cardiomyocyte 
protection (Juhaszova et al., 2004; Hausenloy et al., 2005; see review of Heusch et al., 2015). 
However, the specific roles of this kinase in cardioprotection still not clear. Moreover, GSK-3β is an 
important target of the RISK pathway and has been linked to cardioprotection elicited by IPC as 
well as IpostC (Gomez et al., 2008). This was explained by the fact that phosphorylation and 
inactivation of this kinase allows the dephosphorylation of the outer mitochondrial membrane 
(OMM) and voltage-dependent anion channel (VDAC), which may enable mitochondrial 
depolarization, reduction of calcium accumulation and generation of ROS. This in turn, leads to 
inhibition of the MPTP at the time of reperfusion (Heusch et al., 2010) and prevention of cell 
death. Similarly, hexokinase II, a glycolytic enzyme, another mediator of PKB/Akt, has been 
thought to be cardioprotective by maintaining the outer mitochondrial membrane (OMM) and 
attenuating free radicals generation (Nederlof et al., 2014). 
1.5.3 Mitogen activated protein kinases (MAPKs) 
MAPKs are groups of kinases which have been identified in different species, and include: ERKs (1, 
2, 3, 4 and 5), c-Jun amino-terminal kinases (JNK 1, 2 and 3) as well as p38 MAPK isoforms (α, β, γ 
and δ) (Chen et al., 1992; Kyriakis and Avruch., 2001).  
1.5.3.1 ERK p44/p42 MAPK 
ERKp44/p42 MAPK (ERK1/2) are protein-serine/threonine kinases that bind to docking sites on 
their targets and phosphorylate them at Ser/Thr-Pro motifs (Yang et al., 2003). They have been 
considered to be downstream in the Ras-Raf-MEK-ERK signal transduction pathway (Roskoski et 
al., 2012). This pathway has a crucial role in regulating a substantial number of processes including 
cell survival, metabolism, proliferation, and transcription. ERKp44/p42 are expressed in various 
tissues and have 83% amino acid homology (Chen at al., 1992). In addition, intense activation of 
these two kinases has been observed in response to osmotic stress, growth factors, cytokines, as 
well as some ligands of the heterotrimeric GPCRs (Lewis et al., 1998). Cell surface receptors such 
as tyrosine kinases and GPCRs transmit activating signalling to the Raf/MEK/ERK cascade via 
different isoforms of the small GTP-binding protein Ras (Neufeld et al., 2000). Upstream MEK1/2 
stimulates the phosphorylation of human ERKp44/p42 at Tyr204/187 and then Thr202/185 
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(Roskoski et al., 2012). The phosphorylation of both tyrosine and threonine residues are 
essentially required for activation of ERKp44/p42. 
It has been shown that ERKp44/p42 could be phosphorylated in response to the short cycles of 
ischaemia / reperfusion before a sustained ischaemic insult (Fryer et al., 2001). Furthermore, it 
was suggested that mediator factors such as adenosine, ROS, or protein kinase C (PKC) act to 
mediate ERKp44/p42 activation at the time of reperfusion (Hausenloy et al., 2005; Samavati et al., 
2002). Activation of ERKp44/p42 was illustrated to form complexes with mitochondrial PKCε which 
subsequently inhibits the MPTP and elicit cardioprotection (Baines et al., 2002; 2003) (see a review 
of Hausenloy et al., 2005) 
1.5.3.2 P38 MAPK 
P38 MAPK is a class of mitogen-activated protein kinases which are responsive to stress stimuli, 
such as cytokines, ultraviolent irradiation, heat shock, and osmotic shock (Han and Lee, 1994). 
Four p38 MAP kinases have been identified, p38-α (MAPK14), β (MAPK11), γ (MAPK12 / ERK6), 
and δ (MAPK13 / SAPK4) (Kariakis and Avruch, 2003). A number of studies have shown that p38 
MAPK activation during ischaemia exacerbates myocardial damage (Barankic et al., 2000). Its 
activation also aggravates cardiovascular pathologies such as cardiomyocyte remodelling, 
arrhythmias and cardiac failure (Wang et al., 2012; Dejong et al., 2013; Engel et al., 2006). 
Therefore, it was suggested that inhibition of this kinase should be beneficial and confers 
cardioprotection (Pompo et al., 1994; Martin et al., 2001, Marais et al., 2001). Although p38 is 
stimulated by and involved in lethal ischaemic injury, it has also been identified to be a crucial role 
player in triggering the protection of IPC, since inhibition of its activation during this phase 
attenuates protection (Marais et al 2001). It has been suggested that transient p38 activation 
during short preconditioning cycles of ischaemia might be responsible for attenuated p38 
activation during subsequent lethal prolonged ischaemia (Nagarkatti and Sha’afi, 1998; Marais et 
al., 2001; Sanada et al., 2001).  
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1.5.3.3 C-Jun amino-terminal kinases (JNK) 
This kinase has three different isoforms (JNK1, JNK2, and JNK3, also known as stress-activated 
protein kinases, SAPKα, SAPKβ, and SAPKγ respectively). The JNKs are strongly activated in 
response to stress stimuli such as UV irradiation, osmotic shock, and cytokines (Enslen and Davis et 
al., 2001). JNK kinase signaling pathways are activated to a lesser extent or not activated during 
ischaemia. However, they could be activated strongly during reperfusion (Barankcik et al., 1997; 
Knight and Buxton, 1996). Furthermore, JNK/SAPK stimulation has been demonstrated to be an 
important element during an IPC protocol (Ping et al., 1999; Fryer et al., 2001). This was 
recognized when IPC increased JNKs activities (Ping et al., 1999). Similarly, pharmacological 
preconditioning was also shown to activate JNKs (Barankcik et al., 1999). 
 
1.6 Pharmacological preconditioning  
 
Over the past two decades the increasing interest in the mechanism of cardioprotective pathways 
involved in ischaemic preconditioning has led to the identification of a number of pharmacological 
targets, capable of cardioprotection against ischaemia-reperfusion injury. Pharmacological agents 
that have been investigated in this regard include adenosine (Toombs et al., 1992), statins (Leferet 
al., 1999), erythropoietin (Wright et al., 2004), P-selectin antagonists (Kumar et al., 1999), 
cyclosporine (Massoudyet al., 1997) and metoprolol (Ibanez et al., 2007). Conditioning the heart 
with such drugs, i.e. pharmacological preconditioning can easily be applied clinically and would 
prevent the need for an invasive IPC protocol. 
It has been well recognized that accumulation of the second messenger, cyclic adenosine 
monophosphate (cAMP), during sustained ischaemia plays an important role in mediating 
cardiomyocyte damage (Marks et al, 2003). Conversely, cAMP has also been shown to act as a 
trigger of IPC, since it was demonstrated to be significantly increased at the end of each 
preconditioning episode suggesting a role for the Beta-adrenergic receptor (β-AR) signalling 
pathways in this process (Lochner et al., 1998, 2000). Therefore, it has been suggested that 
pharmacological activation of this pathway might be able to provide protection against ischaemia. 
This was first demonstrated by Asimakis et al., 1994, who reported that pharmacological 
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preconditioning with isoproterenol protected against ischaemia. It was subsequently reported that 
transient β-AR stimulation with ligands such as isoproterenol and dobutamine mimicked IPC and 
elicited protection against subsequent long period of ischaemia. This phenomenon was called β-
preconditioning (Lochner et al 1999; Miyawaki and Ashraf., 1997; Nasa et al., 1997; Salie et al., 
2011). Furthermore, it was illustrated that transient Beta 2-adrenergic receptor stimulation with 
formoterol (1 nM) (β2PC), followed by a 5 min washout before index ischaemia elicits 
cardioprotection similar to ischaemic preconditioning (Salie et al., unpublished data). Investigation 
and elucidation of the mechanism of β-preconditioning, opened new avenues into the specific 
characters of β-AR subtypes and their role in cardioprotection.  
 
1.7 The role of the Beta-adrenergic signalling pathway in cardioprotection 
1.7.1 Beta-adrenergic receptors (β-ARs) 
It is now well known that cardiovascular function is regulated by three different β-adrenergic 
receptor subtypes, β1- , β2- and β3-AR. A fourth beta adrenergic receptor (β4-AR) has been 
suggested and described in human atrial and adipose tissue (Kaumann et al., 1997), (for review 
see Gauthier et al., 2000). Stimulation of sympathetic β-adrenergic receptors regulates a diversity 
of physiological processes such as cardiac contractility, carbohydrate and fat metabolism as well as 
cell survival and death (Zheng et al., 2005). β-adrenergic receptor blockers have been shown to 
play a key role in the management of cardiovascular disease by improvement of coronary 
circulation, protection against apoptosis and reduction of infarction (Reiken et al., 2003). Although 
these β -blockers mainly target the β 1- and β 2-receptors, the β3-AR has recently emerged as a 
potential target in the treatment of heart disease. 
 
These receptors belong to the superfamily of GPCRs and comprise of a single 408 amino acid 
residue peptide chain (Fig. 1.2). It possesses seven transmembrane (TM) segments, linked with 
three intracellular and three extracellular loops (formed by hydrophobic stretches containing 
about 21–28 residues). Furthermore, it has an extracellular amino acid (N)-terminal and carboxyl 
(C)-terminal loop located intracellulary. In 1967, Lands et al, classified β-ARs into β1-AR and β2-AR, 
as cardiac/lipolytic and vascular/bronchial subtypes respectively. Subsequently, the gene encoding 
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the β2-AR was successfully cloned (Dixon et al., 1986). In the next several years, many GPCRs were 
cloned, including human β1-AR (Feielle et al., 1987) and human β3-AR, using pharmacological and 
cloning methods (Emorine et al., 1989). 
 
β1- and β2-ARs functionally coexist in cardiomycytes of many mammalian species including 
humans (Brodde et al., 1991), with striking qualitative and quantitative differences in their 
functions and signalling mechanisms (Xiao et al., 2001). In the human heart the β1-AR is the 
predominate receptor and it is equally distributed in all parts of the heart (Brodde et al., 1991; 
Myslivecek et al., 2006). β1- and β2-ARS are expressed at a ratio of about 70-80 %: 30-20 % in the 
ventricles (Brodde et al., 1991) and 60-70 %: 40-30 % in the atria, both of which have positive 
inotropic and chronotropic effects. However, the β3-AR shares about 40-50 % amino acid 
sequence similarity with the β1-and β2-ARs.  
 
 
 
 
 
 
 
 
 
 
 
Fig.1.2 Structure of human β3-AR (Strosberg et al., 2000a) 
Furthermore, the gene that encodes the β3-AR in humans has intron while the classical 1- and 
2-ARs are intronless (for reviews see Perrone and Scilimati, 2010; Gauthier et al., 1996). 
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The β3-AR differs structurally and pharmacologically from the other two subtypes (Bylund et al., 
1994). Both β1-and β2-ARs have serine and threonine residues in the intracellular C-terminus tail 
that act as substrate for G protein-coupled receptor kinases and for phosphorylation by the cAMP-
dependent protein kinase PKA (Gauthier et al., 1996; 1998). In contrast, the β3-AR lacks a PKA 
phosphorylation site and has fewer serine and threonine residues in the C-terminus tail which may 
explain the resistance of these receptors to short term agonist–promoted desensitizationin vitro 
and in vivo (Strosberg et al., 1993; Liggett et al., 1993). Desensitization is a process in which the 
cell desensitizes itself from the continuous stimulus of catecholamines and the process includes (i) 
uncoupling of the receptors from the stimulatory guanine nucleotide-binding protein (Gs); (ii) 
sequestration of the receptors away from the cell surface; (iii) downregulation of cellular receptor 
complement. In addition, protein kinase A (PKA) activates the β-adrenergic receptor kinase 
(βARK), a specific protein that phosphorylates only the active, agonist-occupied form of several G-
protein-coupled receptors (Benovic et al., 1988), which subsequently promotes the binding of 
another protein, called β-arrestin, which was suggested to be the cause of uncoupling of receptors 
from the Gs protein (Lohse et al., 1990). 
 
Despite the fact that the β3-ARs have some structural differences between species, it has been 
shown that there is a high degree of sequence homology: approximately 80–90% between human, 
bovine, rodent, and canine β3-AR. Furthermore, the human, monkey, and bovine β3-ARs are more 
similar to each other than to the rodent, especially in the first TM segment (Perrone et al., 2010). 
Since the gene encoding human β3-AR was cloned in 1989 (Emorine et al., 1989), it has been 
subsequently identified in several species, including rat, mouse (Strosberg and Pietri-Rouxel et al., 
1996), bovine, monkey, dog (Strosberg et al., 1997), sheep and goat (Forrest and Hickford, 2000). 
Moreover, the β3-AR subtype was recognized in a variety of tissues, including the coronary 
vascular bed (Strosberg et al., 1997), mammalian heart (Gauthier et al., 1998; Kaumann et al., 
1997), bladder, uterus, colon, pancreas, and central nervous system (Emorine et al., 1994; Grazia 
and Scilimati, 2010). In addition, it was also recognized in adipose tissue and skeletal muscle, 
where its activation promotes lipolysis and energy expenditure (Arch J R., 2002; Emorine et al., 
1994). The β3-AR subtype can be considered a drug target for the treatment of different 
pathologies such as obesity, type 2 diabetes, cachexia, metabolic syndrome, heart failure, anxiety 
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and depressive disorders, preterm labor, overactive bladder, control of colon motility, and as 
coadjuvants in colon cancer therapy (Perrone and Scilimati, 2010). Despite the fact that several 
agonists and antagonists have been used in the study of the β3-AR, the investigation of its precise 
function and regulation has been hampered by the lack of highly specific agonists/antagonists 
(Vrydag et al., 2007). 
 
The β3-AR is pharmacologically characterized by the following set of criteria: (i) it is potentially and 
selectively stimulated by agonists such as BRL37344 and SR58611A, which have a low affinity for 
other β1- and β2-ARs (Arch and Kaumann, 1993; Emorine et al., 1994); (ii) it is partially activated 
by several β1- and/or β2-AR antagonists, such as cyanopindolol, bucindolol and CGP 12177A (Blin 
et al., 1993); (iii) it is weakly antagonized by conventional β-AR antagonists such as propranolol 
and nadolol and (iv) the β3-AR is selectively antagonized by nonselective β-AR antagonists such as 
bupranolol (Langin et al., 1991) and the selective β3-AR antagonist SR 59230A (Kaumann and 
Molenaar, 1996; Arch, 2002). 
 
1.7.1.1 β3-AR agonists 
Two different classes of β3-AR agonists have been described, the first class includes the phenyl-
ethanolamines, such as BRL37344, SR58611A, and CL316243; however, BRL37344 and SR58611A 
also have a low affinity for β1- and β2-AR stimulation. The second class consists of the 
aryloxypropanolamines, including CGP12177A and cyanopindolol, in addition to L-755507, which 
activate cloned human and rhesus monkey β3-ARs much more potently than the other two 
classical β1- and β2-ARs (Ursino et al., 2009). Interestingly, a study by Gauthier et al., 1996, using 
human endomyocardial biopsies obtained from the right interventricular septum of cardiac 
transplant and open-heart surgery patients, demonstrated that β3-AR stimulation by some 
selective agonists in the presence of nadolol, a β1- and β2- adrenergic receptor antagonist, 
resulted in negative inotropic effects with an order of potency: BRL37344> SR58611A≈ 
CL316243>CGP12177A. Notably, BRL37344 induced a dose-dependent negative inotropic effect at 
concentrations ranging from 0.1 nM to 1 mM (Gauthier et al., 1996); similarly, SR58611A was also 
observed to have a dose-dependent negative inotropic effect. However, a previous in vivo study 
using dogs, clearly demonstrated that β3-AR agonists, BRL37344 and CGP12177A, when 
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administered intravenously, produced a positive chronotropic effect (Tavernier et al, 1992). Since 
these effects were not observed in denervated animals (Shen et al., 1994), it was concluded that 
the positive chronotropic effect was a result of a baroreceptor reflex in response to the sudden 
drop in blood pressure mediated by the vasodilatory effects of β3-AR agonists (Weeldon et al., 
1993 and 1994). 
Currently, a substantial number of scientific papers have been published, describing nebivolol, not 
only as a third generation selective antagonist of β1-ARs, but also as a β3-AR agonist, in the heart 
as well as some vasculature systems (Ferro et al., 2006; Quanget al., 2009 and Aragon et al., 2011). 
Nebivolol has been considered to be a highly cardioselective β1-AR blocker, and it has no 
antagonistic activity for alpha-adrenergic receptors (α-ARs) (Janssen et al., 1989). Furthermore, it 
possesses vasodilation effects mediated by NO dependent pathways. In 1994, Bowman et al was 
the first to provide strong evidence that the vasodilatory effect of nebivolol was mediated by NO. 
Infusion of nebivolol into the dorsal hand veins of healthy men previously injected with 
phenylephrine, produced vasorelaxation of veins and this effect was completely abolished by L-
NMMA, a NO-synthase inhibitor. Since then, a substantial number of studies confirmed Bowman's 
hypothesis (Cockcroft et al., 1995; Altwegg et al., 2000). Therefore, nebivolol was clinically licensed 
to be used in the treatment of essential hypertension (Ferro et al., 2006). In addition to its ability 
to cause peripheral vasodilation, nebivolol has recently been shown to improve cardiac 
dysfunction by enhancing the ejection fraction (EF %) after its administration during reperfusion 
for 4 weeks (Sorrentino et al., 2011). In addition, it has been shown that nebivolol, both in human 
myocardium and coronary microcirculation, induces NO-dependent negative inotropic effects and 
vasodilatation through activating β3-ARs (Dessy et al., 2005; Gauthier et al., 2011) 
1.7.1.2 β3-AR antagonists 
Although the β3-ARs could be blocked with very weak affinity by typical β-AR antagonists, they are 
particularly blocked by β3-AR antagonists such as SR59230A which is characteristically a selective 
antagonist of the rodent β3-AR; however, this compound has no selective antagonist activity 
against the human β3-AR (Gauthier et al., 2011). On the other hand, two more selective 
antagonists, L-748328 and L-748337of human cloned β3-AR have been described and it has been 
shown to have a low affinity for rodent β3-ARs (Candelore et al., 1999). Therefore, in the study of 
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3 adrenergic receptors, the selectivity of antagonists and the types of animal models or the 
species should be taken into account. 
 
1.7.2 The classical/ traditional view of β-AR signalling in the heart 
          The dual coupling to Gi and Gs proteins of β2-and β3-AR but not β1-AR 
Despite many similarities, β1-AR and β2-AR couple to distinct signal transduction pathways to 
elicit different cellular responses with regard to the G protein. In other words, the β1-AR subtype 
couples exclusively to Gs protein, which activates the Gs–AC–cAMP–PKA pathway. This in turn, 
phosphorylates target proteins involved in metabolic regulation, growth control, muscle 
contraction as well as cell survival or death (Zheng et al., 2005). In contrast, β2-AR couples to both 
Gs and Gi proteins giving rise to functionally opposing pathways. Coupling of β2-ARs to Gi proteins 
activates the Gi–GβY–-PI3K-Akt pathway, which in turn, leads to functional localization and 
inhibition of the Gs-AC-cAMP-PKA signalling and protects the cardiomyocytes against apoptosis 
(Zheng et al., 2005). Subsequently, it was also shown that the β3-AR couples to both Gs and Gi 
proteins (Zheng et al., 2005; Sato et al., 2007) and possesses the same classical intracellular 
signalling pathways as β1- and β2-ARs (Fig.1.3). 
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Fig.1.3 signalling pathways of cardiac β-ARs (Zheng et al., 2005) 
In the heart, the beta adrenergic pathways are the primary means of increasing cardiac 
performance in response to acute or chronic stress. However, depending on the tissue type, β3-AR 
stimulation leads to either opposite or comparable functional effects to those produced by 
stimulation of β1- and β2-ARs. The β3-AR is activated at higher concentrations of catecholamines 
than the β1- and β2-adrenergic receptors and once activated; the receptor would deliver a more 
sustained intracellular signal (Lafontan et al., 1994). This may suggest that following prolonged 
activation by the sympathetic nervous system as in the case of prolonged ischaemia, the β3-AR-
mediated response might be preserved, whereas the β1- and β2-adrenergic mediated responses 
are diminished (Gauthier et al.,2000).  
1.7.3 Intracellular signalling pathways of β3-AR stimulation in cardiovascular tissue 
β3-AR and its downstream signalling pathways have been recognized as novel modulators of heart 
function. Despite the fact that most of the available information about the β3-ARs signalling has 
been obtained in studies of adipocytes, recent studies revealed that these signalling pathways 
could be consistently generated in cardiac tissues (Gauthier et al., 2000). Therefore, increasing 
evidence puts the spotlight on the involvement of β3-ARs, via eNOS, in the production of cyclic 3, 
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5, guanosine monophosphate (cGMP) (Dessy and Balligand, 2010). A previous study by Gauthier et 
al., 2000 has concluded that concurrent activation of cAMP-dependent positive (β1- and β2-ARs) 
and NO-dependent negative (β3-ARs) inotropic pathways within the same cardiomyocyte would 
provide an integration-point between the adrenergic receptors-mediated stimulation of cardiac 
contraction. According to this hypothesis, the β3-ARs-mediated pathway would function as a 
countervailing ‘rescue’ mechanism preventing cardiomyocyte damage from excessive stimulation 
by β1- and β2-ARs (Gauthier et al., 2000). To summarize, β3-ARs are stimulated at high 
catecholamine concentrations and induce negative inotropic effects, serving as a “brake” to 
protect the heart from catecholamine overstimulation (Niu et al., 2012). 
It has been demonstrated that overexpression of β3-AR in human cardiomyocytes is sufficient to 
stimulate the signalling transduction pathway that ultimately, via increased cGMP and NO 
production, induces negative inotropic effects (Tavernier et al., 2003). NO exerts many of its 
effects through its target molecule, soluble guanylyl cyclase (sGC). The activated form of (sGC) 
converts the guanosine triphosphate (GTP) to cyclic 3, 5, guanosine monophosphate (cGMP), the 
common downstream second messenger of natriuretic peptides and nitric oxide. cGMP, in turn, 
exerts its physiological effect in cardiomyocytes, through the activation of protein kinase G (PKG) 
signalling, and the activation and/ or inhibition of phosphodiesterases (PDEs) (Boris M., 2012).  
It was suggested that the eNOS-NO-GC-cGMP-PKG-dependent signalling pathway plays an 
important role in attenuating hypertrophic remodelling, through the inhibition of the Ca2+ 
dependent signalling pathways (Hammond and Balligand, 2012). Thefore, cGMP signals would be a 
promising target for manipulating cardiovascular pathologies. Furthermore, it was also illustrated 
that an increase in NO formation through modulation of eNOS activity after the application of 
BRL37344 is specifically coupled to stimulation of the cardiac β3-AR. In contrast, activation of 
eNOS, after stimulation of β3-AR in β3−/− mice with the selective agonist BRL37344, was 
completely absent (Gauthier et al., 1998). 
 
In human atria, β3-AR stimulation has been illustrated to produce positive inotropic effects by the 
phosphorylation of calcium channels and increase of intracellular Ca2+ (Skeberdis et al., 2008), 
suggesting that the β3-AR may be coupled to the stimulatory Gs protein as well. However, this 
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receptor is also capable of exerting negative inotropic effects in human ventricles by coupling to 
the inhibitory Gi protein and stimulating NO dependent signalling pathways (Gauthier et al., 1996; 
1998). 
Recently, a study by Aragon et al (2011) has showed that administration of nebivolol or BRL37344 
at the time of reperfusion caused a significant reduction in infarct size of mice subjected to 45 min 
of myocardial ischaemia. They also demonstrated that these protective effects were mediated by 
rapid activation of eNOS and nNOS and increased production of NO and its metabolites.  
Subsequently, a more recent study investigated the mechanisms involved in the cardioprotective 
effects of β3-AR in mice as well as pigs and found that pre-reperfusion administration of BRL37344 
decreased infarct size and improved long-term LV contractile function in both animal models 
(Garcia-Prieto et al., 2014). Using isolated cardiomyocytes exposed to hypoxia/reoxygenation, 
these workers also showed that selective β3-AR stimulation is associated with an increase in 
PKB/Akt phosphorylation and NO formation, thus exerting an Akt-eNOS-NO dependent effect in 
cardiomyocytes which ultimately induced a delay in the opening of the MPTP and thus enhanced 
cell viability. Therefore, it could be concluded that activation of cardiac β3-AR elicits protection via 
inhibition of MPTP, through a PKB/Akt-NOS-NO-cGMP-PKG dependent signalling pathway.  
1.8 Nitric oxide 
Intensive research over several years identified the so-called endothelium-derived relaxing factor 
(EDRF) indeed as nitric oxide (NO). It was subsequently recognized as an essential signalling 
molecule in the cardiovascular and nervous system. In the cardiovascular system endothelial cells 
are the main source of NO production, with the platelets contributing to a lesser extent. Its main 
function is to cause vasodilatation, inhibit platelet aggregation as well as vascular smooth muscle 
cell (VSMC) proliferation. In mammalian cells it is synthesized from the amino acid L-arginine by 
oxidation of one of the terminal guanidine nitrogen atoms to produce L-citrulline and NO (Palmer 
et al., 1988). This reaction is catalyzed by the enzyme NO synthase (NOS). Three main isoforms of 
this enzyme have been identified thus far. Endothelial nitric oxide synthase (eNOS) was first 
purified and cloned from vascular endothelial cells (Lamas et al., 1992) and platelets (Mehta et al., 
1995). Neuronal nitric oxide synthase (nNOS) although first identified in both central and 
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peripheral nervous tissues (Papapetropoulos et al., 1999), it has been detected also outside the 
nervous system. Inducible nitric oxide synthase (iNOS) is an inducible form of the enzyme, and 
found in vascular smooth muscle cells (VSMCs) (Beasley et al., 1991). The latter isoform binds to 
calmodulin even in the presence of low concentrations of Ca2+ (Lincoln et al., 1997) and its 
activation is independent of intracellular Ca2+ levels. Both eNOS and nNOS are constitutively 
activated, and their activation is dependent upon the binding of calmodulin via increased 
intracellular Ca2+ levels (Forstermann et al., 1991., Lincoln et al., 1997). However, eNOS can also 
be activated independently of Ca2+ elevation, by phosphorylation of various serine residues of 
some of protein kinases (Dimmeler et al., 1999) (for review see Queen and Ferro, 2006). The 
activity of eNOS is modulated by phosphorylation of the following sites: serine 1177 (phospho-
eNOS Ser1177), threonine 497 (phospho-eNOS Thr497), serine 633 (phospho-eNOS Ser633) and 
serine 114 (phospho-eNOS Ser114) (Kolluru et al., 2010). Phosphorylation at Ser 1177 activates 
eNOS, whereas phosphorylation at Ser 114 and Thr 497 inhibits its activity (Fleming et al., 2003; 
Mount et al., 2007). 
 
Convincing evidence exists regarding a link between activation of β3-ARs and NO generation 
(Gauthier et al., 1996; Tavenier et al., 2003; Queen et al., 2006; Niu et al., 2012; Aragon et al., 
2011). For example, it has been shown that β3-AR in human hearts stimulated the production of 
NO through the activation of eNOS present in ventricular myocytes as well as in vascular 
endothelial cells (Gauthier et al., 1998; Brunner et al., 2001). 
β3-ARs-eNOS coupling was first illustrated by Pott et al (2003) who tested the effect of the β3-AR 
agonist (BRL37344) on human atria. A subsequent study by the same group revealed that β3-ARs-
eNOS coupling was mediated by the PI3-K/Akt pathway and modulated by phosphorylation at the 
serine 1177 and serine 114 residues (Brixius et al., 2004). Recently, studies have shown that 
stimulation of β3-AR, leads to production of NO also via nNOS in diabetic and aged rat hearts 
(Birenbaum et al., 2008). These studies suggest that although β3-AR's functional significance may 
not be apparent in healthy subjects, it has the capability to signal through nNOS and change the 
contractile response. However it should be borne in mind that the β3-AR-agonist BRL37344 is 
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selective for rodents, therefore, extrapolating these findings to humans was restricted (Queen et 
al., 2006).  
Over the past decade, it has been shown that the plasma level of NO metabolites, nitrite and 
nitrosothiols, increase during exercise in both rodents and humans (Brown et al., 2005; Zhang et 
al., 2006). Therefore, some studies have emerged suggesting that exercise training elicits 
sustainable cardioprotection against IRI in animal as well as after acute myocardial infarction in 
humans (Calvert et al., 2011; Lennon et al., 2004; Brown et al., 2005). Subsequently, it was shown 
that voluntary exercise reduces myocardial injury in mice following a 4 week training period and 
that these protective effects can be sustained for at least 1 week after cessation of training. These 
cardioprotective effects of exercise were mediated by changes in the phosphorylation status of 
eNOS which, in turn, were mediated by β3-AR stimulation (Lefer et al., 2011). 
The cardiac effects of 3-stimulated release of NO have been shown to be attenuated by the non-
specific NOS inhibitor L-NAME (Nappet al. 2009). Similarly, the protective effects of nebivolol were 
significantly inhibited by the selective β3-AR blocker (SR59230A) and NOS inhibitor L-NAME (Zhang 
et al., 2014), indicating that cardioprotective effects of β3-AR are mediated through a NOS-NO 
dependent pathway. In addition, it was observed that nNOS was overexpressed in failing hearts 
after AMI, suggesting that nNOS might also be contributing to β3-AR induced cardiac regulation 
(Niu et al., 2012). 
A recent in vivo study demonstrated that selective stimulation of β3-AR with BRL37344 prevented 
cardiac dysfunction, significantly attenuated the apoptotic effects of IRI, and inhibited fibrosis via 
activation of eNOS and nNOS, which contributed to the enhanced cardiac function after AMI (Niu 
et al., 2014). In this study, C57BL6/J mice were used and MI was performed by ligation of left 
anterior descending (LAD) coronary artery via left thoracotomy under anesthesia with 2% 
isoflurane. Animals were divided into four groups, sham group, MI group, and the last two groups 
were treated with BRL37344 (MI+BRL37344 group) or SR59230A (MI+SR59230A group) 
respectively at 0.1 mg/kg/hour for one day, and the mice were sacrificed 4 weeks after the 
operation. The sham group underwent the same operation but suture under left coronary artery 
was not tied. The expression of β3-AR was significantly increased in the MI group as well as 
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MI+BRL37344 treated group. Interestingly, no changes were noted in the expression of cardiac β1-
AR and β2-AR (Niu et al., 2014). This study also illustrated that BRL37344 treatment increased the 
expression of phospho-eNOS Ser1177, and decreased the level of phospho-eNOS Thr497, 
indicating significant activation of eNOS. Moreover, it significantly increased expression of nNOS 
and phospho-nNOS, while having no effect on iNOS expression.  
Similarly, a concurrent in vivo study provided supportive evidence that nebivolol decreased 
cardiomyocyte apoptosis, improved cardiac function after IR via activation of β3-AR-nNOS and 
eNOS dependent pathways and enhanced cardiac β3-AR expression after MI (Zhang et al., 2014). 
Interestingly, the protective effects of nebivolol were inhibited by β3-AR antagonist SR59230A and 
NOS inhibitor L-NAME. C57BL6/J mice were also used in this study and divided into 5 groups, 
sham, MI, MI+nebivolol, MI+nebivolol+SR59230A, and MI+nebivolol+L-NAME. All the above drugs 
were administered for 4 weeks after the MI procedure respectively. Moreover, the expression 
ratio of β3-AR to β-actin in nebivolol treated group (MI+nebivolol) was significantly increased 
although it was significantly decreased in the MI group compared with the sham group (Zhang et 
al., 2014). Taken together, these data demonstrated that the cardioprotective effects of BRL37344 
as well as nebivolol are mediated by β3-AR stimulation, and that both eNOS and nNOS are 
involved in the release of NO after β3-AR activation (Birixius et al., 2006). The participation of 
nNOS in cardioprotection was further confirmed by Aragon and coworkers (2011) who reported 
that the nebivolol-induced cardioprotection was associated with increased expression of nNOS, 
while the drug failed to reduce infarct size in nNOS knockout mice. Confirmatory evidence is still 
needed to prove which NOS isoform is the principal factor in β3-AR mediated cardioprotection. 
Therefore further studies, revealing the specific signalling mechanisms by which β3-AR produces 
its effects in the myocardium are needed before clinical application in MI. 
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Hypothesis 
Regarding the role of the β3-AR in MI, the exact physiological and pathophysiological roles of the 
β3-AR remain to be elucidated and have to be defined more accurately by selective manipulation 
of this receptor. While most recent studies (Aragon et al., 2011; Zhang et al., 2014; Niu et al., 
2014; and Garcia-Prieto et al 2014) support a significant role for β3-AR in modulation of 
reperfusion injury after AMI, we hypothesize that selective β3-AR stimulation during ischaemia / 
reperfusion may be cardioprotective, whereas selective β3-AR inhibition may prove useful in the 
end stages of sustained ischaemia and early reperfusion. Therefore, in this study we intended to 
investigate the possible cardioprotective effects of β3-AR modulation prior to; at the end of 
sustained ischaemia and / or early reperfusion.  
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Research Aims 
 
In view of the above, the aims of this study were to explore the mechanisms involved in the 
cardioprotective response of β3-AR modulation. The following aspects were investigated: 
 
1. The cardioprotective effects of β3-AR activation before the onset of sustained 
ischaemia (pre-treatment) (PT) by application of a β3-AR agonist or antagonist before 
regional ischaemia followed by reperfusion. Functional recovery and infarct size were 
assessed. 
 
2. The cardioprotective effects of β3-AR activation during ischaemia and early 
reperfusion. The β3-AR agonist or antagonist was administered during last 10 min 
regional ischaemia (per-treatment) (PerT) and /or during the first 10 minutes of 
reperfusion (post-treatment) (PostT). Functional recovery and infarct size were 
assessed. 
 
3. Investigation of the role of NOS in β3-AR mediated cardioprotection before regional 
ischaemia (pre-treatment) and during early reperfusion (post-treatment), using the 
NOS inhibitor, L-NAME. Functional recovery and infarct size were assessed. 
  
4. Evaluation of the effects of β3-AR modulation on intracellular signalling pathways (i.e. 
extracellular signal-regulated kinase (ERKp44/p42), phosphoinositide-3-kinase (PI3K) 
/protein kinase B (PKB/Akt), glycogen synthase kinase-3β (GSK-3β) and endothelial 
nitric oxide synthase (eNOS) by Western Blot analysis. 
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2. Materials and methods 
 
 
2.1 Animals 
Male Wistar rats weighing 250 to 350 g were used in this study. The rats were obtained from the 
University of Stellenbosch Central Research Facility, and they had free access to food and water 
prior to experimentation. The project was approved by the Ethics committee of the University of 
Stellenbosch (Faculty of Health Sciences), ethical approval number: P08/05/009. The animals were 
treated according to the revised South African National Standard for the Care and Use of Animals 
for Scientific Purposes (South African Bureau of Standards, SANS 10386, 2008). 
 
2.2 Perfusion Technique 
The rats were euthanized (30 mg pentobarbital/rat) by intraperitoneal injection. The hearts were 
rapidly excised and arrested in ice-cold (4°C) Krebs-Henseleit buffer, containing in mM: NaCl 119; 
NaHCO3 25; KCl 4.75; KH2PO4 1.2; MgSO4 0.6; Na2SO4 0.6; CaCl2 1.25; glucose 10; pH 7.4. The buffer 
was gassed with 95 % O2 and 5 % CO2 prior to and during the perfusion protocol. After removal, 
the hearts were mounted on the aortic cannula of the Neely-Morgan perfusion system and 
perfused retrogradely in a non-recirculating manner, at 100 cm H2O for 15 minutes. During this 
time the left atrium was cannulated to allow atrial perfusion at a preload of 15 cm H2O. After 15 
min of retrograde perfusion, the mode of perfusion was changed to the working heart mode for 
15 minutes, the left ventricle ejecting against a hydrostatic pressure of 100 cm H2O (afterload). 
Subsequent to this stabilization period of 30 minutes, the experiments were continued according 
to the protocols discussed later. The myocardial temperature was monitored by insertion of a 
temperature probe in the coronary sinus and maintained throughout the experiment at 37 °C. 
Drugs were applied via a side-arm into the aortic cannula, while the hearts were retrogradely 
perfused at a pressure of 100 cm H2O. 
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REGIONAL ISCHAEMIA REPERFUSIONSTABILIZATION
Infarct size
1550 50 60 9515 30
2.2.1 Regional ischaemia 
Regional ischaemia was applied by inserting a silk suture underneath and around the proximal left 
anterior descending (LAD) coronary artery. Tightening of the suture resulted in occlusion of the 
coronary artery, cessation of regional myocardial perfusion and a ~33 % reduction in total 
coronary flow. Regional cyanosis of the area of the occluded vessel was also used as an indicator 
of effective occlusion of the vessel. Coronary artery occlusion was maintained for 35 minutes and 
the heart was surrounded by a water-jacketed chamber to maintain the myocardial temperature 
at 36.5oC. Reperfusion was initiated by releasing the ligation and restoration of coronary flow to 
the ischaemic area. Hearts were reperfused retrogradely for 10 minutes, followed by perfusion in 
the working mode for 20 minutes during which time the functional recovery was measured twice. 
This was followed by retrograde perfusion for another 30 minutes, for measurement of infarct size 
(as described below). 
Basic perfusion Protocol 
 
 
 
 
2.2.2 End - points of ischaemic damage  
2.2.2.1 Myocardial Function 
Coronary (Qe) and aortic (Qa) flow rates in ml/minute were measured manually. The aortic 
pressure (mmHg) was obtained through a side branch of the aortic cannula which was connected 
to a Viggo-spectramed pressure transducer. The peak systolic pressure (PSP), diastolic pressure 
and heart rate (HR) were obtained from the recordings made. The following parameters were 
calculated:  
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The mean external power produced by the left ventricle (TW) in mWatts was calculated according 
to the formula of Kannengieser and co-workers (1979): 
 TW = 0.002222(PAO-11.25) (CO) 
             Where  
      PAO = aortic pressure and CO = cardiac output (Qa+ Qe) 
Measurements were made before and after ischaemia, during reperfusion. Functional recovery of 
hearts was determined by expressing post-ischaemic cardiac output and total work as a 
percentage of pre-ischaemic values. 
 
2.2.2.2 Determination of infarct size 
 
At the completion of regional ischaemia and reperfusion, the silk suture around the LAD coronary 
artery was permanently tied and a 0.25% Evans blue solution infused into the heart to outline 
viable tissues. Hearts were removed, frozen, cut into 1-2 mm thick transverse tissue segments and 
incubated in 1 % triphenyltetrazolium chloride (TTC) in phosphate buffer, pH 7.4 for 10-15 
minutes. Damaged tissues take on a deep red coloration, resulting from the reaction of cardiac 
lactate dehydrogenase enzymes with tetrazolium which was subsequently reduced to red TPF 
(1,3,5-triphenylformazan) to form a red formazan / crystalline deposit. Infarcted tissues (areas of 
necrosis) are not stained and have a white colour, since these enzymes have been either 
denatured or degraded. The reaction with TTC was stopped by placing the tissue segments in 10 % 
formalin. Tissue segments were then placed between two glass plates and traced to outline the 
infarcted as well as the area at risk in each ventricular section. The left ventricle area at risk (R) 
and the area of infarct (I) tissue were determined using computerised planimetry (UTHSCSA Image 
Tool program, developed at the University of Texas Health Science Centre at San Antonio, Texas).  
The infarct size was expressed as a percentage of the area at risk (I/R %). 
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2.2.2.3 Western Blotting  
 
The left ventricle of each heart was removed and snap-frozen at the time intervals indicated in the 
protocol section. Immunoblotting and detection of total as well as phosphorylated proteins, total 
ERK p44 / p42 MAP Kinase, phospho-ERKp44/p42 (T202/Y204); total PKB/Akt, phospho-PKB/Akt 
(Ser-473); total GSK-3, phospho-GSK-3 (S9); and total eNOS, phospho-eNOS(Ser-1177), using 
appropriate antibodies from Cell Signalling Technology.  
2.2.2.3.1 Preparation of lysate 
The lysis or protein extraction buffer contained the following: 20 mM Tris-HCl, 1 mM EGTA, 1 mM 
EDTA, 150 mM NaCl, 1 mM -glycerolphosphate, 1 mM NaVO3, 50 µg/ml phenylmethylsulfonyl 
fluoride (PMSF), 10 µg/ml Leupeptin, 10 µg/ml Aprotinin, 1 % Triton. NaVO3 was prepared weekly; 
PMSF was added last to the buffer. Approximately 30 mg tissue was homogenized in 900 μl lysis 
buffer using a polytron homogenizer (2x4 seconds). After incubation on ice for 20 minutes, 
samples were centrifuged at 14500 rpm for 10 min to obtain the cytosolic fraction. The protein 
content of each sample was determined using the Bradford method (Bradford, 1975).The protein 
concentration of all samples were adjusted and equalized with sample and lysis buffer after which 
samples were boiled for 5 min and stored at – 80oC. 
2.2.2.3.2 Western Immunoblot Analysis 
Samples were subjected to electrophoresis on a 12 % or 7.5 % polyacrylamide gel (SDS –PAGE), 
depending on the size of the protein of interest, using the standard BIO-RAD Mini Protean III 
system. The separated proteins were transferred to an Immobilon membrane (Millipore) (Billerica, 
MA, USA: Polyvinylidenedifluoride (PVDF) membrane), using the Trans-Blot®Turbo™ Transfer 
system. Proper protein transfer and equal loading were routinely assessed using Ponceau-s 
staining and corrections were made if necessary. Non-specific binding sites on the membrane 
were blocked with 5% fat free milk (5g) in a 100 ml TBS-Tween (Tris-buffered saline + 0.1 % Tween 
20) for 1-2 hours at room temperature and incubated overnight with the primary antibodies (Cell 
Signalling Technology, Massachusetts, USA) that recognize total or phosphorylated proteins: 
PKB/Akt, ERKp44/p42, GSK-3 and eNOS. The membranes were washed with TBS-T (3x5 min) and 
then incubated with a diluted horseradish peroxidase-labelled secondary antibody (Amersham Life 
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Science, Buckinghamshire, UK). After thorough washing with TBS-T, membranes were covered 
with Enhanced chemiluminescence ECL detective reagent for one minute and briefly exposed with 
the Chemidoc MP Imager System with Image lab 5. Blots were normalized with the Ponceaued 
membranes using Bio-Rad Image lab.5 in Chemi Doc system, to determine equal loading. Data 
were standardized against the negative controls, which were freeze clamped hearts after 30 
minutes retrograde perfusion, to obtain fold increases of kinase activation. Positive controls, 
which were cardiac microvascular endothelial cells treated with 500 nM Okadaic acid for 30 
minutes, were used only with eNOS evaluation.  
 
2. 3 Drugs 
Chemicals used in this study were: selective β3-AR agonist, BRL37344 (1 μМ); selective β3-AR 
antagonist SR59230A (0.1 μМ) and nitric oxide synthase inhibitor, Nitro-L-arginine methyl ester 
hydrochloride, L-NAME (50μM). BRL37344 and SR59230A were dissolved in 
dimethylsulfoxide (DMSO) and the concentration of the DMSO in KREBS buffer was 0.008% and 
0.0008 % respectively. 
 
2.4 Statistical analysis 
 
Results were expressed as mean ± standard error of the mean (SEM). For multiple comparisons 
one or two-way analysis of variance (ANOVA) was utilised (Graph Pad PrismPlus Version 5.0). Post-
hoc testing for differences between selected groups was done using Bonferroni’s method. A p-
value of < 0.05 was considered significant. 
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2.5     Experimental protocols (infarct size protocols) 
2.5.1 Investigating the effect of pretreatment (PT) with the β3-AR agonist, BRL37344 or 
antagonist, SR 59230A on infarct size and functional recovery 
Non-Pretreatment protocol (NPT): hearts were stabilized for 60 minutes and subjected to 35 
minutes regional ischaemia (RI), followed by 60 minutes reperfusion (n=6/group) (Fig.2.1).  
Pre-treatment (PT): hearts were stabilized for 50 minutes, thereafter pre-treated with either a β3-
AR agonist BRL37344 or antagonist SR5923OA for 10 minutes after which the hearts were 
subjected to 35 minutes regional ischaemia RI and 60 minutes reperfusion (n=6 hearts for each 
drug) (Fig.2.2). Haemodynamic parameters were recorded at the end of the 15 minutes working 
heart mode, prior to regional ischaemia, and compared with haemodynamic parameters after 20 
and 30 min reperfusion. Infarct size was assessed at the end of 1h reperfusion. 
 
 
 
 
REGIONAL ISCHAEMIA REPERFUSIONSTABILIZATION
Fig. 2.1  Non-Pretreatment
Infarct size
1550 50 60 9515 30
1550 50 60 9515 30
REGIONAL ISCHAEMIA REPERFUSIONSTABILIZATION
Infarct size
Fig. 2.2  BRL37344 / SR59230A Pre-treatment
10MIN  BRL /SR
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2.5.2 Investigation of the effect of β3-AR stimulation or inhibition during the last 10 minutes of 
regional ischaemia (Per-treatment/PerT) and the first 10 minutes of reperfusion (Post-
treatment/PostT) 
After the stabilization period, hearts were exposed to 35 minutes regional ischaemia. The β3-AR 
agonist BRL37344 or antagonist SR5923OA was administered during the last 10 minutes of 
regional ischaemia (PerT) (Fig.2.3). In another set of experiments hearts were exposed to 
BRL37344 or SR5923OA for 20 min, during the last 10 minutes of RI  as well as the first 10 minutes 
of reperfusion (PerT + PostT), (n=6 hearts for each drug) (Fig.2.4). Measurements were made as 
described above (2.5.1) 
 
 
 
 
 
  
Fig. 2.3  BRL37344 / SR59230A  Per-treatment
REGIONAL ISCHAEMIA REPERFUSIONSTABILIZATION
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Fig. 2.4  BRL37344 / SR 59230A  Per-treatment and Post-treatment
10 MIN  BRL / SR
Infarct size
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2.5.3 Investigation of the effect of the β3-AR agonist, BRL37344 or antagonist, SR5923OA at the 
beginning of reperfusion (post-treatment) 
Hearts in this group were stabilized for 60 minutes, subjected to 35minutes regional ischaemia  
(RI) and BRL37344 or SR5923OA administered during the first 10 minutes of reperfusion (n=6 
hearts for each drug) (Fig.2.5). Measurements were made as described in 2.5.1. 
 
 
 
 
2.5.4 Investigation of the effects β3-AR activation with the agonist BRL37344 during  
ischaemia and subsequent inhibition with the antagonist SR5923OA during reperfusion 
The BRL37344 was administered during the last 10 minutes of regional ischaemia RI, and the 
SR59230A during the first 10 minutes of reperfusion (n=6 hearts) (Fig.2.6). Measurements were 
made as described in 2.5.1. 
 
Infarct size
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Fig. 2.5  BRL37344 / SR59230A  Post-treatment
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2.5.5 Assessment of involvement of nitric oxide synthase (NOS) in β3-AR stimulation before 
regional ischaemia and during reperfusion, using nitric oxide synthase inhibitor (L-NAME) 
Hearts were pre-treated with the nitric oxide synthase inhibitor (L-NAME) alone or in combination 
with BRL37344, for 10 minutes after which the hearts were subjected to 35 minutes regional 
ischaemia RI and 60 minutes reperfusion (Fig.2.7A). 
  
 
 
For the post-treatment protocols, hearts were stabilized for 60 minutes and then subjected to 35 
minutes regional ischaemia (RI); L-NAME or the combination of BRL37344 and L-NAME was 
administered during the first 10 minutes of reperfusion (Fig.2.7B) (n=5-6 hearts). Measurements 
were made as described above. 
Fig. 2.6  BRL37344  Per-treatment and  SR 59230A Post-treatment 
10 MIN  BRL
Infarct size
10 MIN  SR
1550 60 9515 30 85 105
REGIONAL ISCHAEMIA REPERFUSIONSTABILIZATION
1550 50 60 9515 30
REGIONAL ISCHAEMIA REPERFUSIONSTABILIZATION
Infarct size
Fig. 2.7 (A)  L-NAME / BRL37344 + L-NAME Pre-treatment
10MIN LNAME
/ BRL+ L-NAME
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2.6 Evaluation of the effect of β3-AR modulation on signalling pathways (Western Blotting 
      Protocols) 
Hearts (left ventricles only) were cut and freeze-clamped at the indicated time intervals below, for 
subsequent measurements of phosphorylated and total ERKp44/p42, PKB/Akt, GSK-3B, and eNOS 
by Western blot analysis. 
 
2.6.1 Non-pretreatment 
Hearts were stabilized for 60 minutes, followed by 35 minutes RI and only left ventricles freeze-
clamped immediately after 10 min reperfusion (n=3) (Fig.2.8). 
 
 
 
Infarct size
REGIONAL ISCHAEMIA REPERFUSIONSTABILIZATION
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/ BRL + L-NAME
Fig. 2.7 (B)  L-NAME / BRL37344 + L-NAME Post-treatment
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Fig. 2.8  Non-Pretreatment
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2.6.2 β3-AR agonist BRL37344 Pre-treatment 
Hearts were pre-treated with the β3-AR agonist BRL37344 prior to 35 min regional ischaemia and 
only left ventricles freeze-clamped immediately after 10 min reperfusion (n=3) (Fig.2.9). 
 
 
 
2.6.3 β3-AR agonist BRL37344 Per-treatment 
Hearts were stabilized for 60 minutes and subjected to 35 minutes regional ischaemia during 
which BRL37344 was applied at the last 10 min of regional ischaemia and left ventricles freeze-
clamped at 10 min reperfusion (n=3)(Fig.2.10). 
 
 
  
REGIONAL ISCHAEMIA REPERFUSIONSTABILIZATION
Fig. 2.9  BRL37344  Pre-treatment
10 MIN  BRL
Western blot analysis
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Fig. 2.10  BRL37344  Per-treatment
10 MIN  BRL 
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Western blot analysis
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2.6.4 β3-AR agonist BRL37344 Post-treatment 
In this group, hearts were stabilized for 60 minutes and subjected to  35 minutes regional 
ischaemia RI, followed by the administration of BRL37344 during the first 10 minutes of 
reperfusion and the left ventricles freeze-clamped at this point (n=3) (Fig.2.11). 
 
 
 
 
2.6.5 β3-AR agonist BRL37344 Per-treatment and Post-treatment 
After stabilization for 60 minutes and 35 minutes regional ischaemia, BRL37344 was applied during 
the last 10 minutes of regional ischaemia as well as during the first 10 minutes of reperfusion, left 
ventricles freeze-clamped after 10 minutes reperfusion for Western blot analysis (n=3)(Fig.2.12). 
 
 
 
0
REGIONAL ISCHAEMIA REPERFUSIONSTABILIZATION
Fig. 2.11  BRL37344  Post-treatment
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Fig. 2.12  BRL37344 Per + Post-treatment
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2.6.6 β3-AR agonist BRL37344 Per-treatment and β3-AR antagonist SR59230A Post-treatment  
After stabilization for 60 minutes and 35 minutes regional ischaemia, the β3-AR agonist BRL37344 
was applied during the last 10 min of regional ischaemia, the antagonist SR59230A during the first 
10 minutes of reperfusion and left ventricles freeze-clamped at this point (n=3) (Fig.2.13). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
10 MIN  SR 
0 50 60 9515 30 85 105
REGIONAL ISCHAEMIA REPERFUSIONSTABILIZATION
10 MIN  BRL Western blot analysis
Fig. 2.13  BRL37344  Per-treatment   SR59230A  Post-treatment
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3. Results 
 
3. 1 Effect of β3-AR modulations (stimulation and inhibition) on infarct size 
 
3.1.1 β3-AR modulation: Pre-treatment (PT) 
Pre-treatment (PT) was elicited by administration of the selective β3-AR agonist BRL37344, for a 
period of 10 minutes before 35 minutes regional ischaemia (RI), significantly reduced infarct size 
(% infarct size per area at risk: 21.43±2.52, compared to non-pretreatment group (NPT) 
43.17±1.20, p <0.001) (Fig.3.1). Pretreatment with the vehicle, dimethylsulfoxide (DMSO) and the  
 
Fig.3.1: Effect of pre-treatment with vehicle, (DMSO), β3-AR agonist BRL37344, and β3-AR 
antagonist SR59230A on infarct size of heart after 35 min regional ischaemia and 60 min 
reperfusion (n = 6 / group). 
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β3-AR antagonist, SR59230A had no effect on infarct size (% infarct size per area at risk: 
40.94±2.70 and 38.75±2.57 %, respectively compared to NPT group, 43.17±1. 20%).  
 
3.1.2 β3-AR modulation: Per-treatment (PerT) 
Interestingly, when the selective β3-AR agonist BRL37344 was applied during the last 10 minutes 
of regional ischaemia, β3-Per-treatment (PerT), the infarct size was considerably reduced (% 
infarct size per area at risk: 14.94±2.34, compared to the NPT group 43.17±1.20, p < 0.001) 
(Fig.3.2). The application of β3-AR antagonist, SR59230A and DMSO had no effect on infarct size 
(% of infarct size per area at risk:  40.94±2.70 and 44.66±2.80%, respectively, compared to NPT 
group 43.17±1.20).  
 
Fig.3.2: Effect of vehicle DMSO, β3-AR agonist BRL37344, and antagonist SR59230A, treated during 
last 10 min of RI on infarct size (n = 6 / group).      
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3.1.3 β3-AR modulation: Post-treatment (PostT) 
Application of BRL37344 during the first 10 minutes of reperfusion, β3-post-treatment (PostT), 
caused a significant reduction in infarct size as well (% infarct size per area at risk: 19.06±1.81, 
compared to the NPT group 43.17±1.20, p < 0.001). Treatment with the β3-AR antagonist, 
SR59230A (PostT) had no effect on infarct size (% infarct size: 38.14±2.40 compared to NPT and 
DMSO groups, 43.17±1.20 and 38.75±2.57 %, respectively (Fig.3.3). 
 
Fig.3.3: Effect of vehicle, DMSO, β3-AR agonist BRL37344 and antagonist SR59230A, applied 
during first 10 min of reperfusion, on infarct size after 35 min regional ischaemia and 60 
min reperfusion  (n = 6 / group). 
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3.1.4 β3-AR modulation: Per-treatment (PerT) and Post-treatment (PostT) 
Treatment of hearts with β3-AR agonist BRL37344 during the last 10 minutes of regional ischaemia 
as well as during the first 10 minutes of reperfusion, β3-per-treatment and post-treatment 
(PerT+PostT), resulted in a significant reduction in infarct size when compared to non-
pretreatment (NPT) group (% infarct size per area at risk:20.55±2.01 vs 43.17±1.20, p <0.001) 
(Fig.3.4). The groups treated with the antagonist SR59230A and the vehicle DMSO had no effects 
on infarct size (% infarct size: 34.44±1.88 and 38.75±2.57 %, respectively, compared to NPT group 
43.17±1.20%-   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.3.4: Effect of vehicle DMSO, β3-AR agonist BRL37344 and SR59230A, applied during last 10 
min of RI as well as first 10 min of reperfusion, and effect of BRL37344 applied during RI 
and SR59230A during reperfusion on infarct size of heart exposed to 35 min regional 
ischaemia and 60 min reperfusion  (n = 6 / group). 
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Surprisingly, administration of BRL37344 during the last 10 min of regional ischaemia and the 
antagonist SR59230A at the onset of reperfusion, [BRL (PerT) + SR (PostT)], significantly reduced 
infarct size (% infarct size per area at risk: 20.78±3.02 vs NPT, p <0.001) (Fig.3.4). 
 
3.1.5 The effect of NOS inhibition with the nitric oxide synthase inhibitor L-NAME on the infarct 
size 
 
The nitric oxide synthase inhibitor, Nitro-L-arginine methyl ester hydrochloride (L-NAME), 
administered alone, before regional ischaemia, L-NAME (PT) and during reperfusion, L-NAME 
(PostT), had no effect on infarct size, (% infarct size per area at risk: 39.86±3.67 and 34.70±2.22, 
respectively). However, the reduction in infarct size elicited by the β3-AR agonist, BRL37344, 
administered 10 minutes before regional ischaemia and in another group at the first 10 min of 
reperfusion, was abolished by L-NAME, when administered in combination with BRL37344 for 10 
minutes before regional ischaemia, BRL37344+L-NAME (PT) (% infarct size per area at risk: 
41.48±3.18 vs BRL37344 (PT) 21.43±2.52, p <0.001) or during first 10 minutes of reperfusion, 
BRL37344+L-NAME (PostT) (% infarct size per area at risk: 35.75±3.54 vs BRL37344 (PostT) 
19.06±1.81, p <0.001) (Fig.3.5) (A), (B) . 
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Fig.3.5A: Effects of L-NAME, β3-AR agonist BRL37344, and the combination of L-NAME and 
BRL37344, administered at 10 min before regional ischaemia, on infarct size after 35 min 
regional ischaemia and 60 min reperfusion. 
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Fig.3.5B: Effects of L-NAME, β3-AR agonist BRL37344, and the combination of both L-NAME and 
BRL37344, applied at first 10 min of reperfusion, on infarct size after 35 min regional 
ischaemia and 60 min reperfusion. (n = 6 / group). 
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3.2 Western blot analysis of total and phosphorylated PKB/Akt, ERKp44 / p42 MAPKinase, GSK-
3β and eNOS after treatment with β3-AR agonist BRL37344 or the antagonist SR59230A 
Since none of the protocols with the selective β3-AR antagonist SR59230A showed any kinase 
activation with western blotting, we excluded these data.  The only protocol of significance was 
where the selective β3-AR agonist BRL37344 were applied during the last 10 min of RI and the 
selective β3-AR antagonist SR59230A during the first 10 minutes of reperfusion [BRL37344 (PerT) 
& SR59230A (PostT)].  
3.2.1 Activation of PKB/Akt 
Total PKB/Akt showed no significant changes between the different groups and interventions. 
However, the administration of the selective β3-AR agonist BRL37344 before RI BRL37344 (PT), 
significantly increased phospho-PKB/Akt (fold increase: 2.92±0.22, p< 0.01 vs NPT). Also, when the 
β3-AR agonist was applied during the last 10 minutes of regional ischaemia BRL37344 (PerT), 
phospho-PKB/Akt was significantly increased (5.54±0.43, p<0.01 vs NPT and PT) (Fig.3.6a). 
Activation of phospho-PKB/Akt when BRL37344 was applied during the first 10 minutes of 
reperfusion BRL37344 (PostT) was also higher than the NPT and control groups (fold increase: 
4.73±0.47), however, this activation was found not to be significant. A significant increase in 
phospho-PKB/Akt was observed when BRL37344 was administered during the last 10 minutes of 
regional ischaemia as well as at the onset of reperfusion for 10 minutes, BRL37344 (PerT+PostT) 
(fold increase: 14.2±3.7, p<0.01 vs NPT and p<0.05 vs BRL37344 (PostT) (Fig.3.6b). Furthermore, 
when the β3-AR was stimulated with BRL37344 during late regional ischaemia and inhibited with 
SR59230A at the start of reperfusion, [BRL37344 (PerT) & SR59230A (PostT)], increased the 
phospho-PKB/Akt: fold increase: 6.60±0.7. Even though, it was decreased when compared to the 
BRL37344 (PerT+PostT) group, this reduction was found not to be significant (Fig.3.6b). 
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Fig.3.6 (a): Representative blots for PKB/Akt activation after stimulation of the β3-AR with 
BRL37344 prior to RI BRL37344 (PT) or during last 10 min of RI BRL37344 (PerT) 
(n=3/group). 
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Fig.3.6 (b): Representative blots for PKB/Akt activation after stimulation of the β3-AR with 
BRL37344 at beginning of reperfusion BRL37344 (PostT); during last 10 min RI and 
the onset of reperfusion BRL37344 (PertT+PostT); and lastly when BRL37344 was- 
Phospho-PKB
Total PKB
-Ve C NPT BRL37344
(PostT)
BRL37344
(PerT+PostT)
BRL37344 (PerT)& 
SR59230A (PostT)
C
O
N
TR
O
L
N
PT
B
R
L3
73
44
 (P
os
tT
)
B
R
L3
73
44
 (P
er
T+
P
os
tT
)
B
R
L3
73
44
 (P
er
T)
 &
 S
R
(P
os
tT
)
0
2
4
6
8
10
12
14
16
18
20


 p<0.01 vs NPT
 p<0.05 vs BRL37344 (PostT)
P
K
B
 A
c
ti
v
a
ti
o
n
 (
F
o
ld
 I
n
c
re
a
s
e
)
Stellenbosch University  https://scholar.sun.ac.za
52 
 
administered during the last 10 min of RI followed by the antagonist SR59230Aduring 
the first 10 min of reperfusion [BRL37344 (PerT) &SR59230A (PostT)] (n=3/group). 
 
3.2.2 Activation of ERKp44/42 
Total ERKp44/p42, did not show any significant changes between the different groups. Although 
phospho-ERKp44/p42 did not show differences between the different interventions when 
compared with the non-treated group, the activation obtained in the different groups was 
significantly higher than in the controls. An increase in ERKp44/p42 (fold increase: 1.82±0.06 and 
1.83±0.08, respectively, p<0.05 vs control) was observed in hearts not receiving any treatment 
(NPT). An increase in ERKp44/p42 activation (fold increase: 1.87±0.16, p<0.05 vs control and 
1.97±0.16 p<0.01, vs control, respectively) was observed in the group treated during regional 
ischaemia BRL37344 (PerT). However the group treated before regional ischaemia did not show 
significant increase (Fig.3.7 a). 
Similarly, BRL37344 administered during reperfusion, BRL37344 (PostT), resulted in a 3.9±0.34 and 
3.3±0.11 fold increase in ERKp44/p42, respectively (p<0.01 vs control and <0.05 vs control and 
NPT groups, respectively). Phospho-ERKp44/p42 also significantly increased when BRL37344 was 
applied during both regional ischaemia and reperfusion BRL37344 (PerT+PostT) (the fold increase 
of ERKp44/p42 were 4.24±0.80 and 4.02±0.43, p<0.01 vs control, respectively). 
Furthermore, a 3.35± 0.56 and 3.88±0.78 fold increase in ERKp44/p42 activation was observed, 
when the β3-AR stimulated during regional ischaemia and inhibited during reperfusion [BRL37344 
(PerT) & SR59230A (PostT)], p<0.05 and 0.01 vs controls, respectively (Fig.3.7 b). 
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Fig.3.7 (a): Representative blots for ERKp44/p42 activation after stimulation of β3-AR with 
(BRL37344) before BRL37344 (PT) and during last 10 min BRL37344 (PerT) of regional 
ischaemia (n=3/group) 
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Fig.3.7 (b): Representative blots forERKp44/p42 activation after stimulation of β3-AR with the- 
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   BRL37344 at beginning of reperfusion (BRL37344 (PostT), during last 10 min RI as    
well as first 10 min reperfusion (BRL37344 (PerT+PostT); and lastly when BRL37344-
was applied during regional ischaemia and the antagonist SR59230A during 
reperfusion [BRL37344 (PerT) & SR59230A (PostT)] (n=3/group). 
 
3.2.3 Activation of Glycogen synthase kinase-3β (GSK-3β) 
Stimulation of β3-AR with β3-AR agonist BRL37344 during pre-treatment (PT), per-treatment 
(PerT), post-tratment (PostT) did not phosphorylate GSK-3β protein (Fig.3.8 a) and (Fig.3.8 b). 
However, a significant phosphorylation of GSK-3β was observed when β3-AR stimulation occurred 
during both regional ischaemia and reperfusion BRL37344 (PerT+PostT): (68.85±7.73 vs non-
pretreatment NPT: 1.32±0.41, p<0.001). Interestingly, activation of β3-AR with BRL37344 at the 
end of regional ischaemia and its inhibition with SR59230A at the beginning of reperfusion 
[BRL37344 (PerT) & SR59230A (PostT)] also resulted in a significant phosphorylation of GSK-3β, 
however, this phosphorylation was observed to be significantly reduced when compared to 
BRL37344 (PerT+PostT) (Fig.3.8 b). 
 
 
 
Fig.3.8 (a)  Representative blots for Glycogen synthase kinase-3β (GSK-3β) phosphorylation after 
stimulation of β3-AR with BRL37344 before regional ischaemia BRL37344 (PT), and 
during the end of regional ischaemia BRL37344 (PerT). No GSK-3β phosphorylation 
could be seen.  
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Fig.3.8 (b) Representative blots for Glycogen synthase kinase-3β (GSK-3β) phosphorylation after-       
T GSK-3β
P-GSK-3β (S9)
-Ve C NPT BRL37344
(PostT)
BRL37344
(PerT+PostT)
BRL37344 (Per)& 
SR59230A (Post)
C
O
N
TR
O
L
N
P
T
B
R
L3
73
44
 (P
os
tT
)
B
R
L3
73
44
 (P
er
T 
+ 
P
os
tT
)
B
R
L3
73
44
4 
(P
er
T)
 +
 S
R
(P
os
tT
)
0
20
40
60
80
100


 p<0.001 vs NPT & BRL37344 (PostT)
 p<0.05 vs NPT & BRL37344 (PostT)

   p<0.001 vs BRL37344 (PerT) + SR (PostT)
G
S
K
-3

 A
c
ti
v
a
ti
o
n
Stellenbosch University  https://scholar.sun.ac.za
57 
 
                   stimulation of β3-AR with BRL37344 at beginning of reperfusion BRL37344 (PostT);   
during last 10 min of RI as well as first 10 min reperfusion BRL37344 (PerT+PostT); and 
lastly when BRL37344 was applied during RI and the antagonist SR59230A during 
reperfusion [BRL37344 (PerT) &SR59230A (PostT)] (n=3/group). 
 
3.2.4 Involvement of endothelial nitric oxide synthase eNOS in β3-AR stimulation 
Interestingly, endothelial nitric oxide synthase (eNOS) activation followed the same pattern as 
GSK-3β phosphorylation. The application of the selective β3-AR agonist BRL37344 as a PT or PerT 
did not affect eNOS activation Fig.3.9 (a). However, BRL37344 administered during last 10 minutes 
of regional ischaemia as well as the first 10 minutes of reperfusion BRL37344 (PerT + PostT), 
resulted in a 2.82±0.46 fold activation of eNOS-Ser-1177, compared to (NPT) and BRL37344 
(PostT), p<0.01 and 0.05 respectively. β3-AR stimulated with BRL37344 at the end of regional 
ischaemia and inhibited with SR59230A at the beginning of reperfusion [BRL37344 (PerT) & 
SR59230A (PosT)], caused a 2.26±0.48 fold increase of eNOS-Ser-1177 vs (NPT) group, p<0.05) 
Fig.3.9 (b). 
 
 
 
Fig.3.9 (a) Representative blots for eNOS activation after stimulation of β3-AR with BRL37344 
before regional ischaemia BRL37344 (PT), and during the end of regional ischaemia 
BRL37344 (PerT). 
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Fig.3.9 (b) Representative blots for eNOS activation after stimulation of β3-AR with BRL37344 at 
beginning of reperfusion BRL37344 (PostT); during last 10 min of RI as well as first 10 
min reperfusion BRL37344 (PerT + PostT); and the application of BRL37344 during -
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regional ischaemia RI and the antagonist SR59230A during reperfusion [BRL37344 
(PerT) &SR59230A (PostT)] (n=3/group). 
 
3.3 Haemodynamic data results 
3.3.1 Effects of BRL37344 on coronary flow 
It was observed that coronary flow during retrograde perfusion of hearts treated with BRL37344 
was significantly increased by 40-50 % when the drug was administered before RI and at the start 
of reperfusion (data not shown). However, administration of SR59230A had no effects on coronary 
flow. 
3.3.2 Haemodynamic parameters and percentages of functional recovery 
Functional performance of the 8 groups studied before the onset of RI was similar. Functional 
recovery after ischaemia, as reflected in cardiac output and total work, were significantly lower 
than those observed before induction of ischaemia in all groups (See tables 3.1 and 3.2). 
However, in 6 of the 8 groups their recovery was similar except in two groups, namely BRL37344 
(PT) & SR59230A (PostT) and SR59230A (PerT+PostT) which showed a significant reduction 
when compared with the other groups. For example, compared with the NPT group, the % 
recovery in cardiac output was significantly less (post-ischaemic/pre-ischaemic of cardiac output 
recovery: 16.38±10.38% and 21.39±9.79%, respectively compared with NPT 64.00±6.32%, p-
value <0.01). Similarly, the total work of these two groups reflected the same trends: (post-
ischaemic/pre-ischaemic: 14.77±9.34% and 22.02±9.87%, respectively compared with NPT 
58.39±6.20%, p-value <0.01).   
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Protocol Name CF  
ml/min 
AF 
 ml/min 
CO 
ml/min 
HR 
Beat/min 
PSP 
mmHg 
WT 
mWatts 
NPT 16.50±1.31 46.17±1.97 63.67±3.28 302±3.74 93.00±1.03 13.21±0.77 
BRL37344 (PT) 13.00±1.00 39.67±2.65 58.67±6.10 266±17.21 89.83±1.55 10.53±0.77 
BRL37344 (PerT) 14.67±0.98 44.67±3.88 59.67±5.04 295±11.66 90.50±1.70 12.15±1.20 
BRL37344 (PostT) 16.00±1.86 44.67±2.95 61.17±3.93 290±10.82 92.83±0.79 12.62±0.87 
BRL37344 
(PerT+ PostT) 
17.25±0.45 51.75±2.46 69.00±2.95 306±7.22 92.88±0.89 14.27±0.70 
BRL37344(PerT) & 
SR59230A(PostT) 
16.00±1.09 42.40±1.93 58.40±2.31 324±24.43 87.80±1.24 11.44±0.56 
SR59230A (PT) 14.67±0.98 44.00±2.58 58.67±3.52 317±13.16 90.33±0.71 11.78±0.72 
SR59230A (PerT) 16.00±1.15 45.67±3.02 61.67±3.73 306±18.02 91.33±0.55 12.50±0.75 
SR59230A(PostT) 14.67±0.88 41.67±3.32 56.33±3.83 328±28.90 88.17±1.75 10.99±0.92 
SR59230A 
(PerT+ PostT) 
14.44±0.72 43.33±1.52 57.78±2.14 301±19.44 91.44±1.26 11.77±0.51 
L-NAME (PT) 16.00±0.51 45.67±3.2 61.33±3.63 299±12.31 85.48±3.19 12.07±0.96 
LNAME+BRL (PT) 18.33±0.80 50.33±1.5 68.67±2.10 319±14.04 83.83±4.79 13.46±0.61 
L-NAME (PostT) 17.00±1.23 42.33±3.7 59.33±3.67 294±17.7 89.86±3.40 12.10±0.83 
LNAME+BRL 
(PosttT) 
17.67±1.74 45.67±0.6 63.33±1.52 344±33.15 88.67±2.24 12.59±0.42 
 
Table 3.1 Haemodynamic parameters (mean ± standard error) of the different treated groups 
before regional ischaemia. 
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Protocol Name 
 
CF  
ml/min 
AF 
 ml/min 
CO 
ml/min 
HR 
Beat/min 
PSP 
mmHg 
WT 
mWatts 
NPT 16.00±1.03 24.67±2.9 40.33±3.73 311±10.05 84.83±0.98 7.578±0.66 
BRL37344 (PT) 13.83±1.04 20.17±3.6 33.33±3.55 327±33.30 85.00±1.915 6.32±0.73 
BRL37344 (PerT) 11.67±3.40 14.67±4.6 26.33±7.47 247±57.27 66.67±13.40 4.74±1.38 
BRL37344 (PostT) 12.33±2.55 11.33±3.0 23.67±5.09 270±56.54 68.00±13.64 4.307±0.94 
BRL37344 
(PerT+ PostT) 
15.00±0.75 15.50±2.7 30.50±2.99 318±7.61 81.25±0.97 5.543±0.59 
BRL37344(PerT) & 
SR59230A(PostT) 
3.20±3.20* 2.80±2.8* 6.00±6.00* 69±69.80* 16.20±16.20* 1.07±1.07* 
SR59230A (PT) 12.33±2.70 21.83±5.3 34.17±7.84 291±59.30 70.67±14.15 6.43±1.48 
SR59230A (PerT) 11.33±0.98 17.67±2.8 29.00±3.60 305±8.08 81.50±0.92 5.28±0.70 
SR59230A (PostT) 13.92±1.05 17.67±3.3 31.58±3.64 326±25.70 82.00±1.09 5.79±0.70 
SR59230A 
(PerT+ PostT) 
8.11±2.63* 10.00±3.6* 18.11±6.15* 167±54.57* 46.56±14.73* 3.36±1.14* 
L-NAME (PT) 11.00±2.3 19.08±4.9 30.08±7.03 247±51.63 65.45±13.11 5.29±1.24 
LNAME+BRL (PT) 9.66±3.07 21.00±6.6 30.67±9.73 224±71.55 50.67±16.70 5.61±1.77 
L-NAME (PostT) 11.50±2.9 22.00±6.3 33.50±8.99 271±71.34 66.20±16.73 6.20±1.69 
LNAME+BRL 
(PostT) 
10.40±0.97 16.80±2.9 27.20±3.77 351±29.15 81.60±1.28 4.98±0.82 
 
Table 3.2 Haemodynamic parameters (mean ± standard error) of the different treated groups 
after regional ischaemia, * p-value<0.01 vs NPT. 
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4. Discussion 
 
The role of β-adrenergic receptor (βAR) activation as a mediator of cardioprotection is 
undisputed and it has become clear that controlled activation of the β-adrenergic signalling 
pathway may elicit protective responses in the myocardium. For example, it has been 
demonstrated that transient activation of either the β1-AR or the β2-AR can act as a trigger in 
the ischaemic preconditioning (IPC) process (Lochner et al., 1998, 2000). Subsequently, transient 
pharmacological β1- or β2-AR activation with ligands such as isoproterenol, dobutamine or 
formoterol was reported to have similar cardioprotective effects as IPC and elicits protection 
against subsequent long periods of ischaemia (Asimakis et al., 1994; Lochner et al 1999; Salie et 
al., 2011), the so-called beta-preconditioning. Although transient activation of the β3-AR does 
not act as trigger of preconditioning (Salie et al., 2011), it should be pointed out that pre-
treatment with a β3-AR agonist such as BRL37344, without washout prior to sustained ischaemia, 
effectively protects the heart against I/R damage. 
 
It is well-established that up-regulation of the β3-AR population and concomitant β1- and β2-ARs 
down-regulation, in the failing human heart, are induced by the increasing levels of 
catecholamine (Grazia and Scilimati, 2010). Subsequently, activated β3-AR delivers a more 
sustained intracellular signal, resulting from its resistance to short term agonist-promoted 
desensitization (Liggett et al., 1993), making this receptor an ideal target for therapeutic 
intervention. 
 
Previous studies have investigated the capability of cardioprotective interventions or drugs 
administered at the onset of reperfusion to reduce infarct size for example postconditioning 
(IPostC) (Zhao et al., 2003), erythropoietin (Bullard et al., 2005), activators of kinases including 
insulin, insulin-like growth factor-1 (IGF-1) as well as urocortin, atorvastatin and bradykinin 
(Hausenloy et al., 2004).  All these interventions have been illustrated to confer cardioprotection 
through activation of the pro-survival kinases, PI3K-Akt and/or ERK p44/p42 cascades, during the 
first minutes of reperfusion (Bell and Yellon, 2003a; Hausenloy and Yellon, 2004; Hausenloy et 
al., 2005). Furthermore, inhibitors of the MPTP using sanglifehrin-A (Hausenloy et al., 2003) or 
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cyclosporin (Hausenloy et al., 2014; Ong et al., 2015), have also been shown to reduce infarct size 
and improve cardiac functional recovery.  
However, from failed clinical trials (Flaherty et al., 1994), it appears that the window of 
opportunity for successful intervention during reperfusion is very limited. Although protection 
can be initiated at reperfusion, injury also occurs during ischaemia, and the relative contribution 
of each event, probably also depends on the duration of ischaemia (Stephanou et al., 2001). 
Consequently, if cardioprotective strategies can be introduced before or during ischaemia, it is 
possible that they will enhance protection, particularly with longer durations of ischaemia 
(Murphy, and Steenbergen, 2007). Therefore, in the present study the effects of β3-AR 
stimulation with BRL37344 on infarct size were studied at various time intervals, namely, (1) 
before 35 minutes of regional ischaemia (Pre-treatment, PT), (2) during regional ischaemia (only 
last 10 minutes) (Per-treatment,PerT), (3) at the onset of reperfusion (Post-treatment,PostT), and 
(4) during both ischaemic and reperfusion phase (PerT +PostT). To investigate the involvement of 
the RISK pathway as well as the roles of GSK3-β and eNOS in β3-AR modulation at these various 
time intervals of the perfusion protocol, hearts were freeze-clamped at 10 minutes reperfusion 
for Western blot analysis, as this point of reperfusion has been shown to be associated with 
maximal phosphorylation of cardioprotective kinases (Salie et al. unpublished data). 
 
In this study, BRL37344 was used as a selective β3-AR agonist, as it has been shown to be a 
potent selective β3-AR for rodents, however, it was found to be 60% less effective in humans 
than in rats (Blin et al., 1994; Dolan et al., 1994). Moreover, recent studies have shown that 
BRL37344 administration is linked to PKB/Akt activation and NO production (Aragon et al., 2011; 
Gracia et al., 2014). Furthermore, it has been reported that BRL37344 induced a dose-dependent 
negative inotropic effect at concentrations ranging from 0.1nM to 1mM (Gauthier et al., 1996). 
Salie (PhD thesis) also found that BRL37344 at 1M had a profound negative inotropic effect 
when administered to the isolated working rat heart. This effect could be washed out which 
probably accounts for its failure to precondition the heart.  It was also illustrated that BRL37344 
(1M) effectively decreased the amplitude of oxytocin-induced myometrial contractions, as well 
as significantly increased cGMP levels in a BRL37344 group compared to the control group, which 
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were antagonized with SR59230A (1M) (Yurtcu et al., 2006). In addition, it was found that β3-
receptor antagonists SR59230A (1μM) or L-748,337 (3μM) reduced nebivolol-induced NO release 
by approximately 50% in human umbilical vein endothelial cells (HUVECs) (Mason RP et al., 
2013). The concentration-response curves to isoprenaline in pig bladder showed that SR59230A 
(30nM to 1μM) effectively inhibits isoprenaline induced contractions (Yamanishi et al., 2002). 
Consequently, in this study we decided to use BRL37344 at a concentration of 1μM and 
SR59230A at 0.1μМ.  
 
4.1 The effect of β3-AR-stimulation/inhibition on the outcome of ischaemia/reperfusion 
 
The data obtained in this study provide significant evidence for the cardioprotective effects of 
β3-AR stimulation with BRL37344, regardless of its time of administration. This was clearly 
demonstrated by the significant reduction in infarct size, obtained by stimulation of the receptor 
at different times during the I/R protocol (PT, PerT, and/or PostT). However, inhibition of β3-AR 
with the antagonist (SR59230A) had no effect on infarct size (see results section Fig 3.1, 3.2, 3.3 
and 3.4). Interestingly, in all interventions, the reduction in infarct size was not associated with 
an improvement in functional recovery during reperfusion (see results section, tables 3.1 and 
3.2). This could be due to concomitant myocardial stunning, namely postischaemic mechanical 
contractile dysfunction that persists during reperfusion despite the restoration of flow. 
Myocardial stunning has been proposed to be due to either generation of free radicals or calcium 
overload, leading to excitation-contraction uncoupling (Bolli et al., 1998).  
However, it was suggested that β3-AR activates NOS which would lead to increased production 
of NO and cGMP (Tavernier et al., 2003). Increased cGMP is associated with decreased 
intracellular calcium concentration (Hammond and Balligand, 2012) and thus attenuation of 
myocardial stunning. Therefore, in this study, myocardial stunning could be due to a burst of ROS 
production during reperfusion and not calcium overload. Thus future investigations need to be 
done to explore the involvement of ROS production in β3-AR stimulation and its relationship to 
NO and cGMP activation. 
 
A number of in vivo studies have recently also illustrated a reduction in infarct size with β3-AR 
agonist administered during reperfusion, confirming our ex vivo data. For example, 
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administration of BRL37344 during reperfusion after in vivo coronary artery ligation attenuated 
fibrosis and scar formation (Niu et al 2014) and reduced infarct size in both small and large 
animal models of MI/R (Garcia-Prieto et al 2014).  The latter group also showed improved long-
term left ventricular function after β3-AR agonist treatment. Moreover, it was shown that pre-
reperfusion treatment was without effect in cyclophilin-D KO mice, implicating the MPTP in the 
mechanism of protection. It has recently been demonstrated that nebivolol, a third-generation β-
blocker, protects against myocardial infarction via stimulation of β3-AR and the eNOS/nNOS 
pathway (Zhang et al 2014). The study of Aragon and co-workers 2011 also failed to demonstrate 
any significant improvement in cardiac function after reperfusion with nebivolol as well as with 
the selective β3-ARs agonists, BRL37344 and CL316243. This is also probably due to stunning 
since assessment of left ventricular function was done shortly after the MI/R protocol.  
 
4.2 The effect of β3-AR-stimulation at the end of ischaemic phase and its inhibition during           
  reperfusion on the outcome of ischaemia/reperfusion 
With this intervention we intended to investigate whether β3-AR inhibition, using SR59230A at 
the beginning of reperfusion (PostT), could abrogate the beneficial effects of BRL37344 given at 
the end of the ischaemic period (PerT) [BRL37344 (PerT) & SR 59230A (PosT)]. Although these 
interventions had no effect on the significant reduction in infarct size elicited by BRL37344 (PerT) 
alone (see Fig 3.2 and 3.4), it caused the most marked decrease in functional recovery of all 
manipulations studied (see table Table 3.2). The reason for this marked depression in 
postischaemic function is probably due to an effect of SR59230A per se on contractility, since 
administration of this inhibitor alone also markedly reduced myocardial function (Table 3.2). 
These observations clearly illustrate the importance of β3-AR stimulation during the late phase of 
regional ischaemia to bring about potent cardioprotective effects during reperfusion which, in 
this particular protocol, may be due to a reduction in ischaemic injury per se.                                      
 
4.3 The role of NO in the actions of β3-AR stimulation 
In the current study, the increased coronary flow observed during administration of BRL37344 
during retrograde perfusion of hearts (data not shown), suggests a vasodilatation effect, which 
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might implicate NOS and NO as important role players in β3-AR mediated cardioprotection. It 
was previously demonstrated that β3-ARs expressed in the endothelium of human coronary 
arteries mediate vasodilatation via NO production (Dessy et al., 2004). Subsequently, nebivolol, 
although it is a selective β1-AR blocker, has been shown to produce vasodilatation in both 
human and rodent coronary microarteries through stimulation of endothelial β3-ARs and 
subsequent release of NO (Dessy et al., 2005). In the present study the role of NOS and NO 
production in β3-AR–mediated cardioprotection was evaluated by using the non-specific NOS 
inhibitor, L-NAME at concentration of 50 M, as it has been shown in our laboratory that at this 
concentration the cGMP levels were significantly reduced (Lochner et al., 2000).  L-NAME, 
administered in combination with the β3-AR agonist (BRL37344) prior to regional ischaemia, 
BRL37344+L-NAME (PT) or at the onset of reperfusion, BRL37344+L-NAME (PostT), abolished 
cardioprotection as was shown by a significant increase in infarct size in both protocols  (Figs 
3.5a and 3.5b).  
Although several studies suggested that selective β3-AR stimulation elicits its protection by 
activating NOS pathways and release of NO (Zhang et al., 2014; Niu et al., 2014; Aragon et al., 
2011), the exact NOS isoform involved is still being debated. Nebivolol has been shown to 
increase activation of eNOS and expression of nNOS (Aragon et al 2011; Zhang et al 2014,) while 
Niu and coworkers showed that BRL37344 has similar effects. In contrast to the proposed dual 
activation of eNOS and nNOS, other studies suggested that NO release secondary to β3-AR 
activation was exclusively from eNOS (Brixius et al., 2004; 2006), while nNOS and /or iNOS have 
also been  implicated in the β3-AR mediated cardioprotective signalling (Maffei et al., 2007; Niu   
et al., 2012; Calvert et al., 2011).                                                                                                                     
 
In the current study, Western blot results consistently provide supportive evidence for the 
involvement of eNOS in the cardioprotection elicited by selective β3-AR stimulation. Firstly, eNOS 
was significantly activated when BRL37344 was applied at the end of regional ischaemia and 
continued at the start of reperfusion, BRL37344 (PerT+PostT). Secondly, eNOS activation also 
occurred, when the BRL37344 was administered at the end of ischaemia and SR59230A at the 
beginning of reperfusion with [BRL37344 (PerT) & SR 59230A (PostT)] (see Fig.9a and 9b). At the 
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moment we do not have an explanation why the cardioprotection induced by PT, PerT, and PostT 
with BRL37344 was not associated with activation of eNOS. It is possible that activation of eNOS 
occurs very rapidly (within 5-15min after nebivolol administration (Aragon et al 2011) and that is 
no longer detectable after 10min of reperfusion in our protocol. However, this remains to be 
further elucidated. Activation of nNOS and iNOS was not evaluated in the present study, but 
indications are that iNOS is not activated by β3-AR stimulation (Aragon et al 2011; Niu et al 
2014). 
 
4.4 Selective β3-AR modulation and the RISK Pathways: PKB/Akt and ERKp44/42 
 
It is well-established that cardioprotective strategies such as IPC, IpostC and pharmacological 
preconditioning are usually associated with activation of the RISK pathway (ERKp44/p42 and 
PKB/Akt) as well as phosphorylation of its downstream target GSK-3β (Tong et al., 2002; 
Hausenloy and Yellon., 2004; Gomez et al., 2008). Although, the exact mechanism by which the 
RISK pathway inhibits the MPTP is unclear, it has been suggested that phosphorylation of 
PKB/Akt and ERKp44/p42 may activate downstream signalling, such as PKG, GSK-3β, or 
Hexokinase II, or through modulation of MPTP inducing mediators such as oxidative stress, 
calcium overload and pH restoration (for review see Ong et al., 2015). Experimental data has 
suggested that translocation of kinases such as PKB/Akt, ERKp44/p42 and PKG to the 
mitochondria are linked to MPTP inhibition (Ong et al., 2015). Interestingly, we found the 
recruitment of these powerful cardioprotective kinases in our study using pharmacological β3-AR 
stimulation. However, the fact that we used the whole left ventricle (which included tissue 
subjected to ischaemia as well as normal tissue) in preparing our samples for blots; this might 
have masked the protein activation, particularly ERKp44/p42 activation. 
 
4.4.1   PKB/Akt 
 
The present study shows that BRL37344 activates PKB/Akt, regardless of its time of 
administration (see Figs.3.6a and 3.6b). However, the most significant activation of PKB/Akt was 
seen when β3-AR stimulation was applied during both the end of ischaemia and at the beginning 
of reperfusion, BRL37344 (PerT+PostT) (Fig.3.6b). Conversely, stimulation of β3-AR with 
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BRL37344 during late regional ischaemia and its inhibition with SR59230A at the onset of 
reperfusion [BRL37344 (PerT) + SR59230A (PostT)] resulted in a slight, but not significant 
reduction in phospho-PKB/Akt (Fig.3.6b). This intervention was also associated with a significant 
infarct size reduction (see Fig 3.4). It should be noted that a slight decrease in PKB/Akt and eNOS 
activation, even though not significant, can be an important determining factors in cell survival.  
The activation pattern obtained with PKB/Akt correlates better with the reduction in infarct size 
than activation of GSK-3β and eNOS per se. It should be taken into account that PKB/Akt has 
several downstream substrates, not only GSK-3β and eNOS, and many of which are 
cardioprotective in their own respect such as Bad, Caspase 9, and FOXOs. Therefore, elucidation 
the cardioprotective signalling mechanisms, by which the BRL37344 (PT, PerT and PostT) groups 
reduced infarct size, needs intensive investigations to these substrates.  
 It is possible that activation of PKB/Akt is dependent on the period of administration of the β3-
agonist, since the most marked activation of PKB, eNOS and GSK-3β was seen in the BRL 37344 
(PerT+PostT) group. In a recent study Garcia et al (2014) has reported that BRL37344 exerts Akt-
eNOS-NO dependent signals in the isolated adult cardiomyocytes exposed to 
hypoxia/reoxygenation, which essentially inhibits the MPTP opening and therefore increasing 
cardiomyocyte survival. These observations are in agreement with previous findings by Garlid 
and coworkers (2004) that activation of PKB/Akt leads to stimulation of eNOS-NO-cGMP-PKG 
signalling, which subsequently inhibits MPTP opening. At low concentrations, NO inhibits 
opening of the mitochondrial permeability transition pore (West et el., 2008), whereas high 
levels facilitates pore opening. 
 
4.4.2   ERKp44/p42  
ERKp44/p42 activation after stimulation of β3-AR with BRL37344 was not significant in BRL37344 
(PT) and BRL37344 (PerT) groups when compared with NPT (Fig.3.7.a). However, BRL37344 
(PostT) group showed a significant activation (Fig.3.7 b). Furthermore, BRL37344 (PerT+PostT) 
group as well as [BRL37344 (PerT) & SR59230A (PostT)] group showed not significant but 
marginal increases of ERKp44/p42 activation (Fig.3.7 b). Consequently, the role of ERKp44/p42 as 
an important component of RISK pathways in β3-AR stimulation can not be completely excluded 
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or ignored. Therefore, significant activation of ERKp44/p42 and differences between the treated 
groups would be clearly obtained if more samples was used for this analysis. 
 
4.4.3 GSK-3β 
 
The role of phosphorylation and inactivation of GSK-3β leading to inhibition of the mitochondrial 
permeability transition pore and ultimately cardioprotection is well-established (Hausenloy and 
Yellon et al., 2004; Juhaszova et al., 2004; Vigneron et al., 2011; Lochner et al., 2011). However, 
in this study it was found that the reduction in infarct size was not always associated with 
inactivation of GSK-3β: stimulation of β3-AR with BRL37344 before regional ischaemia BRL37344 
(PT); at the end of regional ischaemia BRL37344 (PerT) or at the onset of reperfusion BRL37344 
(PostT), did not phosphorylate GSK-3β protein (Fig.3.8a).  
Significant phosphorylation of GSK-3β was observed in two protocols only namely when the β3-
AR was stimulated at end of ischaemia as well as at the beginning of reperfusion, BRL37344 
(PerT+PostT) (Fig 3.8b) and in hearts exposed to [BRL37344 (PerT) & SR59230A (PostT)] 
(Fig.3.8b). Finally, it is very interesting that PKB was activated by all cardioprotective protocols 
while concomitant phosphorylation of eNOS and GSK-3β occurred in the latter two protocols 
only. Furthermore, the % reduction in infarct size was similar in all BRL37344 groups. 
A clear cut association between the extent of reduction in infarct size and activation of these 
signalling pathways was, however, not forthcoming. Additional studies focussing on the role of 
eNOS and GSK-3β as well as other downstream targets of PKB/Akt in β3-AR-induced 
cardioprotection are required. 
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Summary 
 
 
The data obtained in this study clearly demonstrates that stimulation of the β3-AR elicits 
cardioprotection: treatment of hearts with the selective β3-AR agonist (BRL37344) (1 µM) at 
specific time periods (before, at the end of regional ischaemia and / or the beginning of 
reperfusion), elicited protection against ischaemia/reperfusion injury. This protection was clearly 
illustrated by the significant reduction in infarct size, activation of the PKB/Akt component of 
RISK pathways, and phosphorylation of the downstream targets GSK-3β and eNOS. Hence, β3-AR 
activation provides a convergence of protective pathways which ultimately leads to inhibition of 
MPTP opening as suggested by Garcia-Prieto and coworkers (2014). 
However, in this study the marked reduction in infarct size was not accompanied by an 
improvement in functional recovery during reperfusion. This is a well- established fact in most 
studies using infarct size and functional recovery as endpoints and may be due to concomitant 
stunning which is described as reversible post-ischaemic contractile dysfunction and which may 
obscure the effect of cardioprotection. However, infarct size is regarded as the “gold standard” 
for evaluation of cardioprotection (Kloner et al., 1998; Cohen et al., 1999; Lochner et al., 2003). 
 
Our study suggests that the last 10 minutes of regional ischaemia as well as the first 10 minutes 
of reperfusion are important time intervals to intervene with a selective β3-AR agonist, and this 
was clearly illustrated with application of BRL37344 during late ischaemia and at the beginning of 
reperfusion, BRL37344 (PerT+PostT), which consistently reduced infarct size and caused the 
most significant phosphorylation of the PKB/Akt, GSK-3β and eNOS pathways. Consequently, the 
negative inotropic effects associated with the β3-adrenergic receptor can be effectively 
harnessed to bring about cardioprotection through considerable reduction in infarct size. 
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Novelty of this study 
 
Most recent studies investigating the contribution of this receptor subtype to cardioprotection 
were done in vivo. In this study we made use of an ex vivo approach using the isolated perfused 
rat heart to investigate the cardioprotective effects of stimulation of the β3-AR. This model 
allows for a number of pharmalogical manipulations which are not possible in an in vivo model: 
the MI/R protocol was manipulated by using pharmacological activation/inhibition of β3-AR not 
only during the reperfusion phase but also before and /or during the sustained ischaemic period. 
Our approach also allowed evaluation of the role of the RISK pathway and its links with NO 
production and GSK-3β as downstream target.  
 
Limitations of this study 
 
In the current study the effects of only one selective β3-AR agonist and antagonist were studied. 
Additional agonists should be evaluated, including nebivolol, a third generation beta blocker 
which is selective for the β1-AR but has been shown to induce the β3-AR-NOS-NO dependent 
pathway. Furthermore, involvement of other NOS isoforms, nNOS and iNOS, as well as other 
downstream targets of PKB/Akt, BAD and p70s6K, in the β3-AR cardioprotection needs to be 
investigated. In addition, the significance of the different role players in β3-AR signalling should 
be further unravelled, with particular focus on the role of the MPTP in this regard. 
 
Clinical translation and future studies 
 
The discovery of functional β3-AR in the human heart is expected to shed new light on the 
understanding of the protective effect of therapeutic β-AR inhibition or stimulation in heart 
failure (Bristow, M.R. 2000). Pharmacological manipulation of β3-AR with a selective agonist 
could be easily applied in the clinical setting at the effective time periods – for example after an 
ischaemic episode (or as soon as possible during an ischaemic event) and continued when reflow 
is established as it was well illustrated in this study. Importantly, BRL37344 has been illustrated 
to be a more potent and selective agonist for rodents than humans, which critically limit its usage 
clinically. More studies using large animals are required (as yet there is only one study on pigs by 
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Garcia-Prieto and his group, 2014). Newly characterized antagonists / agonists with better 
selectivity for the human β3-AR are required which will allow more intense testing and may lead 
to the development of new treatment strategies for heart failure. 
To achieve the above objectives, the following experimental approaches could be used:   
human ventricular myocytes, treated in similar settings but with appropriate and more selective 
agonist / antagonists; in vivo studies using regional ischaemia / reperfusion, echocardiography 
and measurement of protein and mRNA levels of inflammatory cytokines; an appropriate cell line 
stably transfected with the human β3-adrenoceptor mRNA. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Stellenbosch University  https://scholar.sun.ac.za
73 
 
References 
 
Agewall, S. 2008. Acute and Stable Coronary Heart Disease: Different Risk Factors. European heart 
journal, 29(16). :1927-1929.Alkhulaifi, A.M. 1997. Preconditioning the Human Heart. Annals of 
the Royal College of Surgeons of England, 79(1). :49-54. 
Altwegg, L.A., d'Uscio, L.V., Barandier, C., Cosentino, F., Yang, Z. & Lüscher, T.F. 2000. Nebivolol 
Induces NO-Mediated Relaxations of Rat Small Mesenteric but Not of Large Elastic 
Arteries. Journal of cardiovascular pharmacology, 36(3). :316-320. 
Andreka, G., Vertesaljai, M., Szantho, G., et al. 2007. Remote Ischaemic Postconditioning Protects 
the Heart during Acute Myocardial Infarction in Pigs. Heart (British Cardiac Society), 93(6). 
:749-752. 
Aragón, J.P., Condit, M.E., Bhushan, S., et al. 2011. Beta3-Adrenoreceptor Stimulation Ameliorates 
Myocardial Ischemia-Reperfusion Injury Via Endothelial Nitric Oxide Synthase and Neuronal 
Nitric Oxide Synthase Activation. Journal of the American College of Cardiology, 58(25). :2683-
2691. 
Arch, J.R. 2002. Β 3-Adrenoceptor Agonists: Potential, Pitfalls and Progress. European journal of 
pharmacology, 440(2). :99-107. 
Arch, J. & Kaumann, A. 1993. Β3 and Atypical β‐Adrenoceptors. Medicinal research reviews, 13(6). 
:663-729. 
Armstrong, S.C., Liu, G.S., Downey, J.M. & Ganote, C.E. 1995. Potassium Channels and 
Preconditioning of Isolated Rabbit Cardiomyocytes: Effects of Glyburide and Pinacidil. Journal 
of Molecular and Cellular Cardiology, 27(8). :1765-1774. 
Asimakis, G.K., Inners-McBride, K., Conti, V.R. & Yang, C.J. 1994. Transient Beta Adrenergic 
Stimulation can Precondition the Rat Heart Against Postischaemic Contractile 
Dysfunction. Cardiovascular research, 28(11). :1726-1734. 
Baines, C.P., Zhang, J., Wang, G.W., et al. 2002. Mitochondrial PKCepsilon and MAPK Form 
Signaling Modules in the Murine Heart: Enhanced Mitochondrial PKCepsilon-MAPK 
Interactions and Differential MAPK Activation in PKCepsilon-Induced 
Cardioprotection. Circulation research, 90(4). :390-397. 
Bankwala, Z., Hale, S.L. & Kloner, R.A. 1994. Alpha-Adrenoceptor Stimulation with Exogenous 
Norepinephrine Or Release of Endogenous Catecholamines Mimics Ischemic 
Preconditioning. Circulation,90(2). :1023-1028. 
Stellenbosch University  https://scholar.sun.ac.za
74 
 
Bankwala, Z., Hale, S.L. & Kloner, R.A. 1994. Alpha-Adrenoceptor Stimulation with Exogenous 
Norepinephrine Or Release of Endogenous Catecholamines Mimics Ischemic 
Preconditioning. Circulation,90(2). :1023-1028. 
Barancik, M., Htun, P. & Schaper, W. 1999. Okadaic Acid and Anisomycin are Protective and 
Stimulate the SAPK/JNK Pathway. Journal of cardiovascular pharmacology, 34(2). :182-190. 
Barancik, M., Htun, P., Strohm, C., Kilian, S. & Schaper, W. 2000. Inhibition of the Cardiac p38-
MAPK Pathway by SB203580 Delays Ischemic Cell Death. Journal of cardiovascular 
pharmacology, 35(3). :474-483. 
Beasley, D., Schwartz, J.H. & Brenner, B.M. 1991. Interleukin 1 Induces Prolonged L-Arginine-
Dependent Cyclic Guanosine Monophosphate and Nitrite Production in Rat Vascular Smooth 
Muscle Cells.The Journal of clinical investigation, 87(2). :602-608. 
Belge, C., Sekkali, B., Tavernier, G., et al. 2007. Cardiomyocyte-Specific Overexpression of beta3-
Adrenoceptors Attenuates the Hypertrophic Response to Catecholamines in 
Vivo. Circulation, 116(16 Supplement). :II_148. 
Bell, R.M. & Yellon, D.M. 2003. Bradykinin Limits Infarction when Administered as an Adjunct to 
Reperfusion in Mouse Heart: The Role of PI3K, Akt and eNOS. Journal of Molecular and 
Cellular Cardiology,35(2). :185-193. 
Bell, R.M. & Yellon, D.M. 2003. Atorvastatin, Administered at the Onset of Reperfusion, and 
Independent Oflipid Lowering, Protects the Myocardiumby Up-Regulating a Pro-Survival 
Pathway. Journal of the American College of Cardiology, 41(3). :508-515. 
Benovic, J.L., Bouvier, M., Caron, M. & Lefkowitz, R. 1988. Regulation of Adenylyl Cyclase-Coupled 
Beta-Adrenergic Receptors. Annual Review of Cell Biology, 4(1). :405-428. 
Bernardi, P. 1992. Modulation of the Mitochondrial Cyclosporin A-Sensitive Permeability 
Transition Pore by the Proton Electrochemical Gradient. Evidence that the Pore can be 
Opened by Membrane Depolarization. The Journal of biological chemistry, 267(13). :8834-
8839. 
Bernier, M., Hearse, D.J. & Manning, A.S. 1986. Reperfusion-Induced Arrhythmias and Oxygen-
Derived Free Radicals. Studies with "Anti-Free Radical" Interventions and a Free Radical-
Generating System in the Isolated Perfused Rat Heart. Circulation research, 58(3). :331-340. 
Birenbaum, A., Tesse, A., Loyer, X., et al. 2008. Involvement of Beta 3-Adrenoceptor in Altered 
Beta-Adrenergic Response in Senescent Heart: Role of Nitric Oxide Synthase 1-Derived Nitric 
Oxide. Anesthesiology, 109(6). :1045-1053. 
Stellenbosch University  https://scholar.sun.ac.za
75 
 
Blin, N., Nahmias, C., Drumare, M.F. & Strosberg, A.D. 1994. Mediation of most Atypical Effects by 
Species Homologues of the β3‐adrenoceptor. British journal of pharmacology, 112(3). :911-
919. 
Blin, N., Camoin, L., Maigret, B. & Strosberg, A.D. 1993. Structural and Conformational Features 
Determining Selective Signal Transduction in the Beta 3-Adrenergic Receptor. Molecular 
pharmacology,44(6). :1094-1104. 
Boengler, K., Hilfiker-Kleiner, D., Heusch, G. & Schulz, R. 2010. Inhibition of Permeability Transition 
Pore Opening by Mitochondrial STAT3 and its Role in Myocardial ischemia/reperfusion. Basic 
research in cardiology, 105(6). :771-785. 
Bolli, R., Becker, L., Gross, G., et al. 2004. Myocardial Protection at a Crossroads: The Need for 
Translation into Clinical Therapy. Circulation research, 95(2). :125-134. 
Bolli, R. & Marban, E. 1999. Molecular and Cellular Mechanisms of Myocardial 
Stunning. Physiological Reviews, 79(2). :609-634. 
Boudewijn, M.T. & Coffer, P.J. 1995. Protein Kinase B (c-Akt) in Phosphatidylinositol-3-OH Kinase 
Signal Transduction. 
Bowman, A., Chen, C. & Ford, G. 1994. Nitric Oxide Mediated Venodilator Effects of 
Nebivolol. British journal of clinical pharmacology, 38(3). :199-204. 
Bristow, M.R. 2000. Beta-Adrenergic Receptor Blockade in Chronic Heart 
Failure. Circulation, 101(5). :558-569. 
Brixius, K., Bloch, W., Pott, C., et al. 2004. Mechanisms of β3‐adrenoceptor‐induced eNOS 
Activation in Right Atrial and Left Ventricular Human Myocardium. British journal of 
pharmacology, 143(8). :1014-1022. 
Brixius, K., Bloch, W., Ziskoven, C., et al. 2006. Β 3-Adrenergic eNOS Stimulation in Left Ventricular 
Murine Myocardium. Canadian journal of physiology and pharmacology, 84(10). :1051-1060. 
Brodde, O.E. 1991. Beta 1- and Beta 2-Adrenoceptors in the Human Heart: Properties, Function, 
and Alterations in Chronic Heart Failure. Pharmacological reviews, 43(2). :203-242. 
Brown, D.A., Chicco, A.J., Jew, K.N., et al. 2005. Cardioprotection Afforded by Chronic Exercise is 
Mediated by the Sarcolemmal, and Not the Mitochondrial, Isoform of the KATP Channel in the 
Rat. The Journal of physiology, 569(3). :913-924. 
Brunner, F., Andrew, P., Wolkart, G., Zechner, R. & Mayer, B. 2001. Myocardial Contractile 
Function and Heart Rate in Mice with Myocyte-Specific Overexpression of Endothelial Nitric 
Oxide Synthase.Circulation, 104(25). :3097-3102. 
Stellenbosch University  https://scholar.sun.ac.za
76 
 
Bullard, A.J., Govewalla, P. & Yellon, D.M. 2005. Erythropoietin Protects the Myocardium Against 
Reperfusion Injury in Vitro and in Vivo. Basic research in cardiology, 100(5). :397-403. 
Bylund, D., Bond, R.A., Clarke, D.E., et al. 1998. Adrenoceptors. The IUPHAR compendium of 
receptor characterization and classification, :58-74. 
Bylund, D.B., Eikenberg, D.C., Hieble, J.P., et al. 1994. International Union of Pharmacology 
Nomenclature of Adrenoceptors. Pharmacological reviews, 46(2). :121-136. 
Calvert, J.W., Condit, M.E., Aragón, J.P., et al. 2011. Exercise Protects Against Myocardial Ischemia-
Reperfusion Injury Via Stimulation of Beta(3)-Adrenergic Receptors and Increased Nitric Oxide 
Signaling: Role of Nitrite and Nitrosothiols. Circulation research, 108(12). :1448-1458. 
Candelore, M.R., Deng, L., Tota, L., et al. 1999. Potent and Selective Human Beta(3)-Adrenergic 
Receptor Antagonists. The Journal of pharmacology and experimental therapeutics, 290(2). 
:649-655. 
Cockcroft, J.R., Chowienczyk, P.J., Brett, S.E., et al. 1995. Nebivolol Vasodilates Human Forearm 
Vasculature: Evidence for an L-arginine/NO-Dependent Mechanism. The Journal of 
pharmacology and experimental therapeutics, 274(3). :1067-1071. 
Cohen, M.V., Yang, X.M. & Downey, J.M. 2007. The pH Hypothesis of Postconditioning: Staccato 
Reperfusion Reintroduces Oxygen and Perpetuates Myocardial Acidosis. Circulation, 115(14). 
:1895-1903. 
Cohen, M.V., Yang, X.M. & Downey, J.M. 1999. Smaller Infarct After Preconditioning does Not 
Predict Extent of Early Functional Improvement of Reperfused Heart. The American Journal of 
Physiology,277(5 Pt 2). :H1754-61. 
Cour, M., Gomez, L., Mewton, N., Ovize, M. & Argaud, L. 2011. Postconditioning: From the Bench 
to Bedside. Journal of cardiovascular pharmacology and therapeutics, 16(2). :117-130. 
Cour, M., Gomez, L., Mewton, N., Ovize, M. & Argaud, L. 2011. Postconditioning: From the Bench 
to Bedside. Journal of cardiovascular pharmacology and therapeutics, 16(2). :117-130. 
De Lean, A., Stadel, J.M. & Lefkowitz, R.J. 1980. A Ternary Complex Model Explains the Agonist-
Specific Binding Properties of the Adenylate Cyclase-Coupled Beta-Adrenergic Receptor. The 
Journal of biological chemistry, 255(15). :7108-7117. 
Dessy, C. & Balligand, J. 2010. Beta3-Adrenergic Receptors in Cardiac and Vascular Tissues: 
Emerging Concepts and Therapeutic Perspectives. Advances in pharmacology, 59:135-163. 
Stellenbosch University  https://scholar.sun.ac.za
77 
 
Dessy, C., Moniotte, S., Ghisdal, P., Havaux, X., Noirhomme, P. & Balligand, J.L. 2004. Endothelial 
beta3-Adrenoceptors Mediate Vasorelaxation of Human Coronary Microarteries through 
Nitric Oxide and Endothelium-Dependent Hyperpolarization. Circulation, 110(8). :948-954. 
Dessy, C., Saliez, J., Ghisdal, P., et al. 2005. Endothelial beta3-Adrenoreceptors Mediate Nitric 
Oxide-Dependent Vasorelaxation of Coronary Microvessels in Response to the Third-
Generation Beta-Blocker Nebivolol. Circulation,112(8). :1198-1205. 
Deuchar, G.A., Opie, L.H. & Lecour, S. 2007. TNFα is Required to Confer Protection in an in Vivo 
Model of Classical Ischaemic Preconditioning. Life Sciences, 80(18). :1686-1691. 
Di Lisa, F., Menabo, R., Canton, M., Barile, M. & Bernardi, P. 2001. Opening of the Mitochondrial 
Permeability Transition Pore Causes Depletion of Mitochondrial and Cytosolic NAD+ and is a 
Causative Event in the Death of Myocytes in Postischemic Reperfusion of the Heart. The 
Journal of biological chemistry, 276(4). :2571-2575. 
Dimmeler, S., Fleming, I., Fisslthaler, B., Hermann, C., Busse, R. & Zeiher, A.M. 1999. Activation of 
Nitric Oxide Synthase in Endothelial Cells by Akt-Dependent 
Phosphorylation. Nature, 399(6736). :601-605. 
Dixon, R., Kobilka, B.K., Strader, D.J., et al.  1997. Cloning of the Gene and cDNA for Mammalian 
Beta-Adrenergic Receptor and Homology with Rhodopsin. Journal of NIH Research, 9:45-52. 
Dixon, R.A., Kobilka, B.K., Strader, D.J., et al. 1986. Cloning of the Gene and cDNA for Mammalian 
ß-Adrenergic Receptor and Homology with Rhodopsin. Nature, 321:75-79. 
Dolan, J.A.,  Muenkel, H.A., Burns, M.G., et al. 1994. Beta-3 Adrenoceptor Selectivity of the 
Dioxolane Dicarboxylate Phenethanolamines. The Journal of pharmacology and experimental 
therapeutics, 269(3). :1000-1006. 
Emorine, L., Blin, N. & Strosberg, A. 1994. The Human β 3-Adrenoceptor: The Search for a 
Physiological Function. Trends in pharmacological sciences, 15(1). :3-7. 
Emorine, L.J., Marullo, S., Briend-Sutren, M.M., et al. 1989. Molecular Characterization of the 
Human Beta 3-Adrenergic Receptor. Science (New York, N.Y.), 245(4922). :1118-1121. 
Enslen, H. & Davis, R.J. 2001. Regulation of MAP Kinases by Docking Domains. Biology of the 
Cell, 93(1‐2). :5-14. 
Fedorov, V.V. & Lozinsky, I.T. 2008. Is the beta3-Adrenergic Receptor a New Target for Treatment 
of Post-Infarct Ventricular Tachyarrhythmias and Prevention of Sudden Cardiac Death? Heart 
Rhythm, 5(2). :298-299. 
Stellenbosch University  https://scholar.sun.ac.za
78 
 
Flaherty, J.T., Pitt, B., Gruber, J.W., et al. 1994. Recombinant Human Superoxide Dismutase (h-
SOD) Fails to Improve Recovery of Ventricular Function in Patients Undergoing Coronary 
Angioplasty for Acute Myocardial Infarction.Circulation, 89(5). :1982-1991. 
Fleming, I. & Busse, R. 2003. Molecular Mechanisms Involved in the Regulation of the Endothelial 
Nitric Oxide Synthase. American journal of physiology.Regulatory, integrative and comparative 
physiology, 284(1). :R1-12. 
Forrest, R. & Hickford, J. 2000. Rapid Communication: Nucleotide Sequences of the Bovine, 
Caprine, and Ovine Beta~ 3-Adrenergic Receptor Genes. JOURNAL OF ANIMAL SCIENCE-
MENASHA THEN ALBANY THEN CHAMPAIGN ILLINOIS-, 78(5). :1397-1398. 
Franke, T.F., Hornik, C.P., Segev, L., Shostak, G.A. & Sugimoto, C. 2003. PI3K/Akt and Apoptosis: 
Size Matters. Oncogene, 22(56). :8983-8998. 
Frazier, E.P., Michel-Reher, M.B., van Loenen, P., et al. 2011. Lack of Evidence that Nebivolol is a β 
3-Adrenoceptor Agonist. European journal of pharmacology, 654(1). :86-91. 
Frielle, T., Collins, S., Daniel, K.W., Caron, M.G., Lefkowitz, R.J. & Kobilka, B.K. 1987. Cloning of the 
cDNA for the Human Beta 1-Adrenergic Receptor. Proceedings of the National Academy of 
Sciences of the United States of America, 84(22). :7920-7924. 
Fryer, R.M., Patel, H.H., Hsu, A.K. & Gross, G.J. 2001. Stress-Activated Protein Kinase 
Phosphorylation during Cardioprotection in the Ischemic Myocardium. American journal of 
physiology.Heart and circulatory physiology, 281(3). :H1184-92. 
Fryer, R.M., Pratt, P.F., Hsu, A.K. & Gross, G.J. 2001. Differential Activation of Extracellular Signal 
Regulated Kinase Isoforms in Preconditioning and Opioid-Induced Cardioprotection. The 
Journal of pharmacology and experimental therapeutics, 296(2). :642-649. 
García-Prieto, J., García-Ruiz, J.M., Sanz-Rosa, D., et al. 2014. Β3 Adrenergic Receptor Selective 
Stimulation during ischemia/reperfusion Improves Cardiac Function in Translational Models 
through Inhibition of mPTP Opening in Cardiomyocytes. Basic research in cardiology, 109(4). 
:1-15. 
Garlid, K., Costa, A., Cohen, M., Downey, J. & Critz, S. 2004. Cyclic GMP and PKG Activate Mito K 
(ATP) Channels in Isolated Mitochondria. Cardiovasc JS Afr, 15(4 Suppl 1). :S5. 
Gauthier, C., Langin, D. & Balligand, J. 2000. Β 3-Adrenoceptors in the Cardiovascular 
System. Trends in pharmacological sciences, 21(11). :426-431. 
Gauthier, C., Rozec, B., Manoury, B. & Balligand, J. 2011. Beta-3 Adrenoceptors as New 
Therapeutic Targets for Cardiovascular Pathologies. Current heart failure reports, 8(3). :184-
192. 
Stellenbosch University  https://scholar.sun.ac.za
79 
 
Gauthier, C., Leblais, V., Kobzik, L., et al. 1998. The Negative Inotropic Effect of beta3-
Adrenoceptor Stimulation is Mediated by Activation of a Nitric Oxide Synthase Pathway in 
Human Ventricle. The Journal of clinical investigation, 102(7). :1377-1384. 
Gauthier, C., Tavernier, G., Charpentier, F., Langin, D. & Le Marec, H. 1996. Functional beta3-
Adrenoceptor in the Human Heart. The Journal of clinical investigation, 98(2). :556-562. 
Genade, S., Moolman, J.A. & Lochner, A. 2001. Opioid Receptor Stimulation Acts as Mediator of 
Protection in Ischaemic Preconditioning. Cardiovascular journal of South Africa : official 
journal for Southern Africa Cardiac Society [and] South African Society of Cardiac 
Practitioners, 12(1). :8-16. 
Gomez, L., Paillard, M., Thibault, H., Derumeaux, G. & Ovize, M. 2008. Inhibition of GSK3beta by 
Postconditioning is Required to Prevent Opening of the Mitochondrial Permeability Transition 
Pore during Reperfusion. Circulation, 117(21). :2761-2768. 
Goto, M., Liu, Y., Yang, X.M., Ardell, J.L., Cohen, M.V. & Downey, J.M. 1995. Role of Bradykinin in 
Protection of Ischemic Preconditioning in Rabbit Hearts. Circulation research, 77(3). :611-621. 
Griffiths, E.J. & Halestrap, A.P. 1995. Mitochondrial Non-Specific Pores Remain Closed during 
Cardiac Ischaemia, but Open upon Reperfusion. Biochem.J, 307:93-98. 
Gross, E.R., Hsu, A.K. & Gross, G.J. 2004. Opioid-Induced Cardioprotection Occurs Via Glycogen 
Synthase Kinase Beta Inhibition during Reperfusion in Intact Rat Hearts. Circulation 
research, 94(7). :960-966. 
Hammond, J. & Balligand, J. 2012. Nitric Oxide Synthase and Cyclic GMP Signaling in Cardiac 
Myocytes: From Contractility to Remodeling. Journal of Molecular and Cellular 
Cardiology, 52(2). :330-340. 
Hausenloy, D.J., Baxter, G., Bell, R., et al. 2010. Translating Novel Strategies for Cardioprotection: 
The Hatter Workshop Recommendations. Basic research in cardiology, 105(6). :677-686. 
Hausenloy, D.J., Lecour, S. & Yellon, D.M. 2011. Reperfusion Injury Salvage Kinase and Survivor 
Activating Factor Enhancement Prosurvival Signaling Pathways in Ischemic Postconditioning: 
Two Sides of the Same Coin. Antioxidants & redox signaling, 14(5). :893-907. 
Hausenloy, D.J., Ong, S. & Yellon, D.M. 2009. The Mitochondrial Permeability Transition Pore as a 
Target for Preconditioning and Postconditioning. Basic research in cardiology, 104(2). :189-
202. 
Hausenloy, D.J., Tsang, A. & Yellon, D.M. 2005. The Reperfusion Injury Salvage Kinase Pathway: A 
Common Target for both Ischemic Preconditioning and Postconditioning. Trends in 
cardiovascular medicine, 15(2). :69-75. 
Stellenbosch University  https://scholar.sun.ac.za
80 
 
Hausenloy, D., Iliodromitis, E.K., Andreadou, I., et al. 2012. Investigating the Signal Transduction 
Pathways Underlying Remote Ischemic Conditioning in the Porcine Heart. Cardiovascular 
drugs and therapy, 26(2). :87-93. 
Hausenloy, D., Kunst, G., Boston-Griffiths, E., et al. 2014. The Effect of Cyclosporin-A on Peri-
Operative Myocardial Injury in Adult Patients Undergoing Coronary Artery Bypass Graft 
Surgery: A Randomised Controlled Clinical Trial. Heart,:heartjnl-2013-304845. 
Hausenloy, D.J., Duchen, M.R. & Yellon, D.M. 2003. Inhibiting Mitochondrial Permeability 
Transition Pore Opening at Reperfusion Protects Against Ischaemia-Reperfusion 
Injury. Cardiovascular research, 60(3). :617-625. 
Hausenloy, D.J. & Yellon, D.M. 2008. Remote Ischaemic Preconditioning: Underlying Mechanisms 
and Clinical Application. Cardiovascular research, 79(3). :377-386. 
Hausenloy, D.J. & Yellon, D.M. 2004. New Directions for Protecting the Heart Against Ischaemia-
Reperfusion Injury: Targeting the Reperfusion Injury Salvage Kinase (RISK)-
Pathway. Cardiovascular research, 61(3). :448-460. 
Heusch, G. 2013. Cardioprotection: Chances and Challenges of its Translation to the Clinic. The 
Lancet, 381(9861). :166-175. 
Heusch, G. 2011. Beta3-Adrenoceptor Activation just Says NO to Myocardial Reperfusion 
Injury. Journal of the American College of Cardiology, 58(25). :2692-2694. 
Heusch, G., Boengler, K. & Schulz, R. 2010. Inhibition of Mitochondrial Permeability Transition Pore 
Opening: The Holy Grail of Cardioprotection. Basic research in cardiology, 105(2). :151-154. 
Heusch, G., Bøtker, H.E., Przyklenk, K., Redington, A. & Yellon, D. 2015. Remote Ischemic 
Conditioning. Journal of the American College of Cardiology, 65(2). :177-195. 
Heusch, G., Bøtker, H.E., Przyklenk, K., Redington, A. & Yellon, D. 2015. Remote Ischemic 
Conditioning. Journal of the American College of Cardiology, 65(2). :177-195. 
Heusch, P., Skyschally, A., Leineweber, K., Haude, M., Erbel, R. & Heusch, G. 2007. The Interaction 
of Coronary Microembolization and Ischemic Preconditioning: A Third Window of 
Cardioprotection through TNF-Alpha. ARCHIVES OF MEDICAL SCIENCE, 3(2). :83. 
Heusch, G. 2015. Molecular Basis of Cardioprotection: Signal Transduction in Ischemic Pre-, Post-, 
and Remote Conditioning. Circulation research, 116(4). :674-699. 
Heusch, G., Boengler, K. & Schulz, R. 2008. Cardioprotection: Nitric Oxide, Protein Kinases, and 
Mitochondria. Circulation, 118(19). :1915-1919. 
Stellenbosch University  https://scholar.sun.ac.za
81 
 
Inagaki, K., Chen, L., Ikeno, F., et al. 2003. Inhibition of Delta-Protein Kinase C Protects Against 
Reperfusion Injury of the Ischemic Heart in Vivo. Circulation, 108(19). :2304-2307. 
Ito, H. 2006. No-Reflow Phenomenon and Prognosis in Patients with Acute Myocardial 
Infarction. Nature clinical practice Cardiovascular medicine, 3(9). :499-506. 
Jonassen, A.K., Sack, M.N., Mjos, O.D. & Yellon, D.M. 2001. Myocardial Protection by Insulin at 
Reperfusion Requires Early Administration and is Mediated Via Akt and p70s6 Kinase Cell-
Survival Signaling. Circulation research, 89(12). :1191-1198. 
Jones, W.K., Fan, G.C., Liao, S., et al.  2009. Peripheral Nociception Associated with Surgical 
Incision Elicits Remote Nonischemic Cardioprotection Via Neurogenic Activation of Protein 
Kinase C Signaling. Circulation, 120(11 Suppl). :S1-9. 
Juhaszova, M., Zorov, D.B., Kim, S.H., et al. 2004. Glycogen Synthase Kinase-3beta Mediates 
Convergence of Protection Signaling to Inhibit the Mitochondrial Permeability Transition 
Pore. The Journal of clinical investigation,113(11). :1535-1549. 
Juhaszova, M., Zorov, D.B., Yaniv, Y., Nuss, H.B., Wang, S. & Sollott, S.J. 2009. Role of Glycogen 
Synthase Kinase-3beta in Cardioprotection. Circulation research, 104(11). :1240-1252. 
Kamohara, S., Hayashi, H., Todaka, M., et al. 1995. Platelet-Derived Growth Factor Triggers 
Translocation of the Insulin-Regulatable Glucose Transporter (Type 4) Predominantly through 
Phosphatidylinositol 3-Kinase Binding Sites on the Receptor. Proceedings of the National 
Academy of Sciences of the United States of America, 92(4). :1077-1081. 
Kaumann, A.J. 1997. Four β-Adrenoceptor Subtypes in the Mammalian Heart. Trends in 
pharmacological sciences, 18(3). :70-76. 
Kaumann, A.J. & Molenaar, P. 1996. Differences between the Third Cardiac β‐adrenoceptor and 
the Colonic β3‐adrenoceptor in the Rat. British journal of pharmacology, 118(8). :2085-2098. 
Kerendi, F., Kin, H.,Halkos, M.E., et al. 2005. Remote Postconditioning. Basic research in 
cardiology, 100(5). :404-412. 
Kharbanda, R.K. 2010. Cardiac Conditioning: A Review of Evolving Strategies to Reduce Ischaemia-
Reperfusion Injury. Heart (British Cardiac Society), 96(15). :1179-1186. 
Khoo, E., Wallis, J., Tsintzas, K., Macdonald, I. & Mansell, P. 2010. Effects of Exenatide on 
Circulating Glucose, Insulin, Glucagon, Cortisol and Catecholamines in Healthy Volunteers 
during Exercise.Diabetologia, 53(1). :139-143. 
Stellenbosch University  https://scholar.sun.ac.za
82 
 
Kloner, R.A., Bolli, R., Marban, E., Reinlib, L. & Braunwald, E. 1998. Medical and Cellular 
Implications of Stunning, Hibernation, and Preconditioning: An NHLBI 
Workshop. Circulation, 97(18). :1848-1867. 
Knight, R.J. & Buxton, D.B. 1996. Stimulation of c-Jun Kinase and Mitogen-Activated Protein Kinase 
by Ischemia and Reperfusion in the Perfused Rat Heart. Biochemical and biophysical research 
communications, 218(1). :83-88. 
Kolluru, G.K., Siamwala, J.H. & Chatterjee, S. 2010. ENOS Phosphorylation in Health and 
Disease. Biochimie, 92(9). :1186-1198. 
Krug, A., Du Mesnil de, R. & Korb, G. 1966. Blood Supply of the Myocardium After Temporary 
Coronary Occlusion. Circulation research, 19(1). :57-62. 
Kuzuya, T.,  Hoshida, S., Yamashita, N., et al.  1993. Delayed Effects of Sublethal Ischemia on the 
Acquisition of Tolerance to Ischemia. Circulation research, 72(6). :1293-1299. 
Kyriakis, J.M. & Avruch, J. 2001. Mammalian Mitogen-Activated Protein Kinase Signal Transduction 
Pathways Activated by Stress and Inflammation. Physiological Reviews, 81(2). :807-869. 
Lacerda, L., Somers, S., Opie, L.H. & Lecour, S. 2009. Ischaemic Postconditioning Protects Against 
Reperfusion Injury Via the SAFE Pathway. Cardiovascular research, 84(2). :201-208. 
Lafontan, M. 1994. Differential Recruitment and Differential Regulation by Physiological Amines of 
Fat Cell β-1, β-2 and β-3 Adrenergic Receptors Expressed in Native Fat Cells and in Transfected 
Cell Lines. Cellular signalling, 6(4). :363-392. 
Lamas, S., Marsden, P.A., Li, G.K., Tempst, P. & Michel, T. 1992. Endothelial Nitric Oxide Synthase: 
Molecular Cloning and Characterization of a Distinct Constitutive Enzyme Isoform. Proceedings 
of the National Academy of Sciences of the United States of America, 89(14). :6348-6352. 
Lands, A., Arnold, A., McAuliff, J., Ludaena, F. & Brown, T. 1967. This 
Week'sCitationClassic. Nature, 214:597-598. 
Langin, D., Portillo, M.P., Saulnier-Blache, J. & Lafontan, M. 1991. Coexistence of Three β-
Adrenoceptor Subtypes in White Fat Cells of various Mammalian Species. European journal of 
pharmacology,199(3). :291-301. 
Lecour, S. 2009. Activation of the Protective Survivor Activating Factor Enhancement (SAFE) 
Pathway Against Reperfusion Injury: Does it Go Beyond the RISK Pathway? Journal of 
Molecular and Cellular Cardiology, 47(1). :32-40. 
Stellenbosch University  https://scholar.sun.ac.za
83 
 
Lefer, A.M., Campbell, B., Shin, Y.K., Scalia, R., Hayward, R. & Lefer, D.J. 1999. Simvastatin 
Preserves the Ischemic-Reperfused Myocardium in Normocholesterolemic Rat 
Hearts. Circulation, 100(2). :178-184. 
Lennon, S.L., Quindry, J., Hamilton, K.L., et al. 2004. Loss of Exercise-Induced Cardioprotection 
After Cessation of Exercise. Journal of applied physiology (Bethesda, Md.: 1985), 96(4). :1299-
1305. 
LESLIE, N. & DOWNES, C. 2004. PTEN Function: How Normal Cells Control it and Tumour Cells Lose 
it. Biochem.J, 382:1-11. 
Leung, C.H., Wang, L., Nielsen, J.M. et al. 2014. Remote Cardioprotection by Transfer of Coronary 
Effluent from Ischemic Preconditioned Rabbit Heart Preserves Mitochondrial Integrity and 
Function Via Adenosine Receptor Activation. Cardiovascular drugs and therapy, 28(1). :7-17. 
Lewis, T.S., Shapiro, P.S. & Ahn, N.G. 1998. Signal Transduction through MAP Kinase 
Cascades. Advances in Cancer Research, 74:49-139. 
Liggett, S.B., Freedman, N.J., Schwinn, D.A. & Lefkowitz, R.J. 1993. Structural Basis for Receptor 
Subtype-Specific Regulation Revealed by a Chimeric Beta 3/beta 2-Adrenergic 
Receptor. Proceedings of the National Academy of Sciences of the United States of 
America, 90(8). :3665-3669. 
Lincoln, J. & Burnstock, G. 1997. Nitric oxide in health and disease. Cambridge University Press 
Liu, G.S., Thornton, J., Van Winkle, D.M., Stanley, A.W., Olsson, R.A. & Downey, J.M. 1991. 
Protection Against Infarction Afforded by Preconditioning is Mediated by A1 Adenosine 
Receptors in Rabbit Heart. Circulation, 84(1). :350-356. 
Lochner, A., Genade, S. & Moolman, J. 2003. Ischemic Preconditioning: Infarct Size is a More 
Reliable Endpoint than Functional Recovery. Basic research in cardiology, 98(5). :337-346. 
Lochner, A., Marais, E., Genade, S., Huisamen, B., Du Toit, E. & Moolman, J. 2009. Protection of the 
Ischaemic Heart: Investigations into the Phenomenon of Ischaemic Preconditioning: Review 
Article.Cardiovascular journal of Africa, 20(1). :43-51. 
Lochner, A., Genade, S., Tromp, E., et al. 1998. Role of cyclic nucleotide phosphodiesterases in 
ischemic preconditioning, Myocardial ischemia and reperfusion. Springer.Pages 169-175 in 
Lochner, A., Marais, E., Toit, E.D. & Moolman, J. 2002. Nitric Oxide Triggers Classic Ischemic 
Preconditioning. Annals of the New York Academy of Sciences, 962(1). :402-414. 
Stellenbosch University  https://scholar.sun.ac.za
84 
 
Lochner, A., Marais, E., Genade, S. & Moolman, J.A. 2000. Nitric Oxide: A Trigger for Classic 
Preconditioning? American journal of physiology.Heart and circulatory physiology, 279(6). 
:H2752-65. 
Lochner, A. 2011. Signalling during an Ischaemic Preconditioning Protocol: New Role 
Players? Cardiovascular research, 90(1). :5-6. 
Lochner, A., Genade, S., Tromp, E., Podzuweit, T. & Moolman, J.A. 1999. Ischemic Preconditioning 
and the Beta-Adrenergic Signal Transduction Pathway. Circulation, 100(9). :958-966. 
Lohse, M.J., Benovic, J.L., Codina, J., Caron, M.G. & Lefkowitz, R.J. 1990. Beta-Arrestin: A Protein 
that Regulates Beta-Adrenergic Receptor Function. Science (New York, N.Y.), 248(4962). :1547-
1550. 
Luo, J., McMullen, J.R., Sobkiw, C.L., et al.  2005. Class IA Phosphoinositide 3-Kinase Regulates 
Heart Size and Physiological Cardiac Hypertrophy. Molecular and cellular biology, 25(21). 
:9491-9502. 
Maffei, A., Di Pardo, A., Carangi, R., et al. 2007. Nebivolol Induces Nitric Oxide Release in the Heart 
through Inducible Nitric Oxide Synthase Activation. Hypertension, 50(4). :652-656. 
Manoury, B., Montiel, V. & Balligand, J.L. 2012. Nitric Oxide Synthase in Post-Ischaemic 
Remodelling: New Pathways and Mechanisms. Cardiovascular research, 94(2). :304-315. 
Marks, A.R. 2003. Calcium and the Heart: A Question of Life and Death. The Journal of clinical 
investigation, 111(5). :597-600. 
Martin, J.L., Avkiran, M., Quinlan, R.A., Cohen, P. & Marber, M.S. 2001. Antiischemic Effects of 
SB203580 are Mediated through the Inhibition of p38alpha Mitogen-Activated Protein Kinase: 
Evidence from Ectopic Expression of an Inhibition-Resistant Kinase. Circulation research, 89(9). 
:750-752. 
Mason, R.P., Jacob, R.F., Corbalan, J.J., Szczesny, D., Matysiak, K. & Malinski, T. 2013. The 
Favorable Kinetics and Balance of Nebivolol-Stimulated Nitric Oxide and Peroxynitrite Release 
in Human Endothelial Cells.BMC pharmacology & toxicology, 14:48-6511-14-48. 
Matsui, T., Tao, J., del Monte, F., et al. 2001. Akt Activation Preserves Cardiac Function and 
Prevents Injury After Transient Cardiac Ischemia in Vivo. Circulation, 104(3). :330-335. 
Matsumoto-Ida, M., Akao, M., Takeda, T., Kato, M. & Kita, T. 2006. Real-Time 2-Photon Imaging of 
Mitochondrial Function in Perfused Rat Hearts Subjected to 
ischemia/reperfusion. Circulation,114(14). :1497-1503. 
Stellenbosch University  https://scholar.sun.ac.za
85 
 
Maulik, N., Yoshida, T., Zu, Y.L., Sato, M., Banerjee, A. & Das, D.K. 1998. Ischemic Preconditioning 
Triggers Tyrosine Kinase Signaling: A Potential Role for MAPKAP Kinase 2. The American 
Journal of Physiology, 275(5 Pt 2). :H1857-64. 
Mehta, J.L., Chen, L.Y., Kone, B.C., Mehta, P. & Turner, P. 1995. Identification of Constitutive and 
Inducible Forms of Nitric Oxide Synthase in Human Platelets. The Journal of laboratory and 
clinical medicine, 125(3). :370-377. 
Miao, Q., Wang, S., Miao, S., Wang, J., Xie, Y. & Yang, Q. 2011. Cardioprotective Effect of Polydatin 
Against ischemia/reperfusion Injury: Roles of Protein Kinase C and Mito K ATP 
Activation.Phytomedicine, 19(1). :8-12. 
Miao, Q., Wang, S., Miao, S., Wang, J., Xie, Y. & Yang, Q. 2011. Cardioprotective Effect of Polydatin 
Against ischemia/reperfusion Injury: Roles of Protein Kinase C and Mito K ATP 
Activation.Phytomedicine, 19(1). :8-12. 
Moens, A.L., Leyton-Mange, J.S., Niu, X., et al. 2009. Adverse Ventricular Remodeling and 
Exacerbated NOS Uncoupling from Pressure-Overload in Mice Lacking the β3-
Adrenoreceptor. Journal of Molecular and Cellular Cardiology, 47(5). :576-585. 
Mount, P.F., Kemp, B.E. & Power, D.A. 2007. Regulation of Endothelial and Myocardial NO 
Synthesis by Multi-Site eNOS Phosphorylation. Journal of Molecular and Cellular 
Cardiology, 42(2). :271-279. 
Murata, M., Akao, M., O'Rourke, B. & Marban, E. 2001. Mitochondrial ATP-Sensitive Potassium 
Channels Attenuate Matrix Ca(2+) Overload during Simulated Ischemia and Reperfusion: 
Possible Mechanism of Cardioprotection. Circulation research, 89(10). :891-898. 
Murphy, E. & Steenbergen, C. 2008. Mechanisms Underlying Acute Protection from Cardiac 
Ischemia-Reperfusion Injury. Physiological Reviews, 88(2). :581-609. 
Murray, Christopher JL and Lopez, Alan D. 1997. .Global Mortality, Disability, and the Contribution 
of Risk Factors: Global Burden of Disease Study.  Journal of the Lancet. 349:1436-1437-1442. 
Murray, C.J. & Lopez, A.D. 1997. Global Mortality, Disability, and the Contribution of Risk Factors: 
Global Burden of Disease Study. The Lancet, 349(9063). :1436-1442. 
Murry, C.E., Jennings, R.B. & Reimer, K.A. 1986. Preconditioning with Ischemia: A Delay of Lethal 
Cell Injury in Ischemic Myocardium. Circulation, 74(5). :1124-1136. 
Mysliveček, J., Nováková, M., Palkovits, M. & Kvetňanský, R. 2006. Distribution of mRNA and 
Binding Sites of Adrenoceptors and Muscarinic Receptors in the Rat Heart. Life Sciences, 79(2). 
:112-120. 
Stellenbosch University  https://scholar.sun.ac.za
86 
 
Naga Prasad, S.V., Laporte, S.A., Chamberlain, D., Caron, M.G., Barak, L. & Rockman, H.A. 2002. 
Phosphoinositide 3-Kinase Regulates beta2-Adrenergic Receptor Endocytosis by AP-2 
Recruitment to the receptor/beta-Arrestin Complex. The Journal of cell biology, 158(3). :563-
575. 
Napp, A., Brixius, K., Pott, C., et al. 2009. Effects of the β 3-Adrenergic Agonist BRL 37344 on 
Endothelial Nitric Oxide Synthase Phosphorylation and Force of Contraction in Human Failing 
Myocardium. Journal of cardiac failure,15(1). :57-67. 
Nebreda, A.R. & Porras, A. 2000. P38 MAP Kinases: Beyond the Stress Response. Trends in 
biochemical sciences, 25(6). :257-260. 
Nederlof, R., Eerbeek, O., Hollmann, M.W., Southworth, R. & Zuurbier, C.J. 2014. Targeting 
Hexokinase II to Mitochondria to Modulate Energy Metabolism and Reduce 
ischaemia‐reperfusion Injury in Heart. British journal of pharmacology, 171(8). :2067-2079. 
Nienaber, J.J., Tachibana, H., Naga Prasad, S.V., et al. 2003. Inhibition of Receptor-Localized PI3K 
Preserves Cardiac Beta-Adrenergic Receptor Function and Ameliorates Pressure Overload 
Heart Failure. The Journal of clinical investigation,112(7). :1067-1079. 
Nishihara, M., Miura, T., Miki, T., et al.  2006. Erythropoietin Affords Additional Cardioprotection 
to Preconditioned Hearts by Enhanced Phosphorylation of Glycogen Synthase Kinase-3 
Beta. American journal of physiology.Heart and circulatory physiology, 291(2). :H748-55. 
Niu, X., Watts, V.L., Cingolani, O.H., et al. 2012. Cardioprotective Effect of Beta-3 Adrenergic 
Receptor Agonism: Role of Neuronal Nitric Oxide Synthase. Journal of the American College of 
Cardiology, 59(22). :1979-1987. 
Niu, X., Zhao, L., Li, X., et al. 2014. Β3-Adrenoreceptor Stimulation Protects Against Myocardial 
Infarction Injury Via eNOS and nNOS Activation. PloS one, 9(6). :e98713. 
Ong, S., Samangouei, P., Kalkhoran, S.B. & Hausenloy, D.J. 2015. The Mitochondrial Permeability 
Transition Pore and its Role in Myocardial Ischemia Reperfusion Injury. Journal of Molecular 
and Cellular Cardiology, 78:23-34. 
Opie, L.H. 2004. Heart physiology from cell to circulation. Philadelphia: Lippincott-Raven publisher, 
4rd Ed, p559-563. 
Oudit, G.Y., Sun, H., Kerfant, B., Crackower, M.A., Penninger, J.M. & Backx, P.H. 2004. The Role of 
Phosphoinositide-3 Kinase and PTEN in Cardiovascular Physiology and Disease. Journal of 
Molecular and Cellular Cardiology, 37(2). :449-471. 
Stellenbosch University  https://scholar.sun.ac.za
87 
 
Ovize, M., Baxter, G.F., Di Lisa, F., et al. 2010. Postconditioning and Protection from Reperfusion 
Injury: Where do we Stand? Position Paper from the Working Group of Cellular Biology of the 
Heart of the European Society of Cardiology. Cardiovascular research, 87(3). :406-423. 
Palmer, R.M., Ashton, D. & Moncada, S. 1988. Vascular Endothelial Cells Synthesize Nitric Oxide 
from L-Arginine. Nature, 333(6174). :664-666. 
Papapetropoulos, A., Rudic, R.D. & Sessa, W.C. 1999. Molecular Control of Nitric Oxide Synthases 
in the Cardiovascular System. Cardiovascular research, 43(3). :509-520. 
Patel, H.H., Moore, J., Hsu, A.K. & Gross, G.J. 2002. Cardioprotection at a Distance: Mesenteric 
Artery Occlusion Protects the Myocardium Via an Opioid Sensitive Mechanism. Journal of 
Molecular and Cellular Cardiology, 34(10). :1317-1323. 
Penna, C., Mancardi, D., Rastaldo, R. & Pagliaro, P. 2009. Cardioprotection: A Radical View: Free 
Radicals in Pre and Postconditioning. Biochimica et Biophysica Acta (BBA)-
Bioenergetics, 1787(7). :781-793. 
Perricone, A.J. & Vander Heide, R.S. 2014. Novel Therapeutic Strategies for Ischemic Heart 
Disease. Pharmacological Research, 89:36-45. 
Perrone, M.G. & Scilimati, A. 2010. B (3)-Adrenoceptor Agonists and (Antagonists as) Inverse 
Agonists History, Perspective, Constitutive Activity, and Stereospecific Binding. Methods 
Enzymol,484:197-230. 
Ping, P., Zhang, J., Huang, S., et al. 1999. PKC-Dependent Activation of p46/p54 JNKs during 
Ischemic Preconditioning in Conscious Rabbits. The American Journal of Physiology, 277(5 Pt 
2). :H1771-85. 
Pott, C., Brixius, K., Bundkirchen, A., et al. 2003. The Preferential β3‐adrenoceptor Agonist BRL 
37344 Increases Force viaβ1‐/β2‐adrenoceptors and Induces Endothelial Nitric Oxide Synthase 
viaβ3‐adrenoceptors in Human Atrial Myocardium. British journal of pharmacology, 138(3). 
:521-529. 
Przyklenk, K., Darling, C.E., Dickson, E.W. & Whittaker, P. 2003. Cardioprotection ‘Outside the 
Box’. Basic research in cardiology, 98(3). :149-157. 
Przyklenk, K., Bauer, B., Ovize, M., Kloner, R.A. & Whittaker, P. 1993. Regional Ischemic 
'Preconditioning' Protects Remote Virgin Myocardium from Subsequent Sustained Coronary 
Occlusion.Circulation, 87(3). :893-899. 
Przyklenk, K., Bauer, B., Ovize, M., Kloner, R.A. & Whittaker, P. 1993. Regional Ischemic 
'Preconditioning' Protects Remote Virgin Myocardium from Subsequent Sustained Coronary 
Occlusion.Circulation, 87(3). :893-899. 
Stellenbosch University  https://scholar.sun.ac.za
88 
 
Przyklenk, K. & Whittaker, P. 2011. Remote Ischemic Preconditioning: Current Knowledge, 
Unresolved Questions, and Future Priorities. Journal of cardiovascular pharmacology and 
therapeutics, 16(3-4). :255-259. 
Przyklenk, K. & Whittaker, P. 2011. Remote Ischemic Preconditioning: Current Knowledge, 
Unresolved Questions, and Future Priorities. Journal of cardiovascular pharmacology and 
therapeutics, 16(3-4). :255-259. 
Queen, L. & Ferro, A. 2006. Β-Adrenergic Receptors and Nitric Oxide Generation in the 
Cardiovascular System. Cellular and Molecular Life Sciences CMLS, 63(9). :1070-1083. 
Rassaf, T., Totzeck, M., Hendgen-Cotta, U.B., Shiva, S., Heusch, G. & Kelm, M. 2014. Circulating 
Nitrite Contributes to Cardioprotection by Remote Ischemic Preconditioning. Circulation 
research,114(10). :1601-1610. 
Reiken, S., Wehrens, X.H., Vest, J.A., et al. 2003. Beta-Blockers Restore Calcium Release Channel 
Function and Improve Cardiac Muscle Performance in Human Heart 
Failure. Circulation, 107(19). :2459-2466. 
Roskoski, R. 2012. ERK1/2 MAP Kinases: Structure, Function, and Regulation. Pharmacological 
research, 66(2). :105-143. 
Salie, R., Moolman, J.A. & Lochner, A. 2012. The Mechanism of Beta-Adrenergic Preconditioning: 
Roles for Adenosine and ROS during Triggering and Mediation. Basic research in 
cardiology, 107(5). :1-22. 
Salie, R., Moolman, J.A. & Lochner, A. 2011. The Role of β-Adrenergic Receptors in the 
Cardioprotective Effects of Beta-Preconditioning (βPC). Cardiovascular drugs and 
therapy, 25(1). :31-46. 
Samavati, L., Monick, M.M., Sanlioglu, S., Buettner, G.R., Oberley, L.W. & Hunninghake, G.W. 2002. 
Mitochondrial K(ATP) Channel Openers Activate the ERK Kinase by an Oxidant-Dependent 
Mechanism. American journal of physiology.Cell physiology, 283(1). :C273-81. 
Sato, M., Hutchinson, D.S., Bengtsson, T., et al. 2005. Functional Domains of the Mouse beta3-
Adrenoceptor Associated with Differential G Protein Coupling. The Journal of pharmacology 
and experimental therapeutics, 315(3). :1354-1361. 
Schmidt, M.R., Smerup, M., Konstantinov, I.E., et al. 2007. Intermittent Peripheral Tissue Ischemia 
during Coronary Ischemia Reduces Myocardial Infarction through a KATP-Dependent 
Mechanism: First Demonstration of Remote Ischemic Perconditioning. American journal of 
physiology.Heart and circulatory physiology, 292(4). :H1883-90. 
Stellenbosch University  https://scholar.sun.ac.za
89 
 
Schultz, J.E., Rose, E., Yao, Z. & Gross, G.J. 1995. Evidence for Involvement of Opioid Receptors in 
Ischemic Preconditioning in Rat Hearts. The American Journal of Physiology, 268(5 Pt 2). 
:H2157-61. 
Seppet, E.K. 2003. Negative Inotropy Starts with the Beta(3)-Adrenoceptor. Cardiovascular 
research, 59(2). :262-265. 
Sharma, V., Bell, R.M. & Yellon, D.M. 2012. Targeting Reperfusion Injury in Acute Myocardial 
Infarction: A Review of Reperfusion Injury Pharmacotherapy. Expert opinion on 
pharmacotherapy, 13(8). :1153-1175. 
Shiki, K. & Hearse, D.J. 1987. Preconditioning of Ischemic Myocardium: Reperfusion-Induced 
Arrhythmias. The American Journal of Physiology, 253(6 Pt 2). :H1470-6. 
Skeberdis, V.A., Gendviliene, V., Zablockaite, D., et al. 2008. Beta3-Adrenergic Receptor Activation 
Increases Human Atrial Tissue Contractility and Stimulates the L-Type Ca2+ Current. The 
Journal of clinical investigation, 118(9). :3219-3227. 
Song, L., Ding, W., Zhao, M., Sun, B. & Zhang, L. 2006. Nitric Oxide Protects Against Oxidative 
Stress Under Heat Stress in the Calluses from Two Ecotypes of Reed. Plant Science, 171(4). 
:449-458. 
Sorrentino, S.A.,  Doerries, C., Manes, C., et al. 2011. Nebivolol Exerts Beneficial Effects on 
Endothelial Function, Early Endothelial Progenitor Cells, Myocardial Neovascularization, and 
Left Ventricular Dysfunction Early After Myocardial Infarction Beyond Conventional β1-
Blockade. Journal of the American College of Cardiology, 57(5). :601-611. 
Staat, P., Rioufol, G., Piot, C., et al. 2005. Postconditioning the Human Heart. Circulation, 112(14). 
:2143-2148. 
Stephanou, A., Brar, B.K., Scarabelli, T.M., et al. 2000. Ischemia-Induced STAT-1 Expression and 
Activation Play a Critical Role in Cardiomyocyte Apoptosis. The Journal of biological 
chemistry, 275(14). :10002-10008. 
Strosberg, A.D. 1997. Structure and Function of the β3-Adrenergic Receptor. Annual Review of 
Pharmacology and Toxicology, 37(1). :421-450. 
Strosberg, A.D. & Pietri-Rouxel, F. 1996. Function and Regulation of the β 3-Adrenoceptor. Trends 
in pharmacological sciences, 17(10). :373-381. 
Strosberg, A.D. & Pietri-Rouxel, F. 1996. Function and Regulation of the β 3-Adrenoceptor. Trends 
in pharmacological sciences, 17(10). :373-381. 
Stellenbosch University  https://scholar.sun.ac.za
90 
 
Sun, H.Y., Wang, N.P., Kerendi, F., et al. 2005. Hypoxic Postconditioning Reduces Cardiomyocyte 
Loss by Inhibiting ROS Generation and Intracellular Ca2+ Overload. American journal of 
physiology.Heart and circulatory physiology,288(4). :H1900-8. 
Tavernier, G., Galitzky, J., Bousquet-Melou, A., Montastruc, J.L. & Berlan, M. 1992. The Positive 
Chronotropic Effect Induced by BRL 37344 and CGP 12177, Two Beta-3 Adrenergic Agonists, 
does Not Involve Cardiac Beta Adrenoceptors but Baroreflex Mechanisms. The Journal of 
pharmacology and experimental therapeutics, 263(3). :1083-1090. 
Thornton, J.D., Liu, G.S., Olsson, R.A. & Downey, J.M. 1992. Intravenous Pretreatment with A1-
Selective Adenosine Analogues Protects the Heart Against Infarction. Circulation, 85(2). :659-
665. 
Tong, H., Imahashi, K., Steenbergen, C. & Murphy, E. 2002. Phosphorylation of Glycogen Synthase 
Kinase-3beta during Preconditioning through a Phosphatidylinositol-3-Kinase--Dependent 
Pathway is Cardioprotective. Circulation research, 90(4). :377-379. 
Toombs, C.F., McGee, S., Johnston, W.E. & Vinten-Johansen, J. 1992. Myocardial Protective Effects 
of Adenosine. Infarct Size Reduction with Pretreatment and Continued Receptor Stimulation 
during Ischemia. Circulation, 86(3). :986-994. 
Tsang, A., Hausenloy, D.J., Mocanu, M.M. & Yellon, D.M. 2004. Postconditioning: A Form of 
"Modified Reperfusion" Protects the Myocardium by Activating the Phosphatidylinositol 3-
Kinase-Akt Pathway. Circulation research, 95(3). :230-232. 
Ursino, M.G., Vasina, V., Raschi, E., Crema, F. & De Ponti, F. 2009. The β 3-Adrenoceptor as a 
Therapeutic Target: Current Perspectives. Pharmacological research, 59(4). :221-234. 
Vigneron, F., Dos Santos, P., Lemoine, S., et al. 2011. GSK-3beta at the Crossroads in the Signalling 
of Heart Preconditioning: Implication of mTOR and Wnt Pathways. Cardiovascular 
research, 90(1). :49-56. 
Vinten-Johansen, J. & Shi, W. 2011. Perconditioning and Postconditioning: Current Knowledge, 
Knowledge Gaps, Barriers to Adoption, and Future Directions. Journal of cardiovascular 
pharmacology and therapeutics, 16(3-4). :260-266. 
Vrydag, W., Alewijnse, A.E. & Michel, M.C. 2009. Do Gene Polymorphisms Alone Or in Combination 
Affect the Function of Human β3‐adrenoceptors? British journal of pharmacology, 156(1). 
:127-134. 
Wang, X.  Cui, L., Joseph, J., et al. 2012. Homocysteine Induces Cardiomyocyte Dysfunction and 
Apoptosis through p38 MAPK-Mediated Increase in Oxidant Stress. Journal of Molecular and 
Cellular Cardiology, 52(3). :753-760. 
Stellenbosch University  https://scholar.sun.ac.za
91 
 
West, M.B., Rokosh, G., Obal, D., et al. 2008. Cardiac Myocyte-Specific Expression of Inducible 
Nitric Oxide Synthase Protects Against ischemia/reperfusion Injury by Preventing 
Mitochondrial Permeability Transition. Circulation,118(19). :1970-1978. 
Wheeldon, N., McDevitt, D. & Lipworth, B. 1994. Cardiac Effects of the Beta 3‐adrenoceptor 
Agonist BRL35135 in Man. British journal of clinical pharmacology, 37(4). :363-369. 
Xiao, R. 2001. Beta-Adrenergic Signaling in the Heart: Dual Coupling of the beta2-Adrenergic 
Receptor to G (s) and G (i) Proteins. Sci STKE, 104:re15. 
Yamanishi, T., Chapple, C.R., Yasuda, K., Yoshida, K. & Chess‐Williams, R. 2002. The Role of 
β3‐adrenoceptors in Mediating Relaxation of Porcine Detrusor Muscle. British journal of 
pharmacology, 135(1). :129-134. 
Yano, N., Suzuki, D., Endoh, M., et al. 2008. Β-Adrenergic Receptor Mediated Protection Against 
Doxorubicin-Induced Apoptosis in Cardiomyocytes: The Impact of High Ambient 
Glucose. Endocrinology, 149(12). :6449-6461. 
Yellon, D.M. & Baxter, G.F. 1995. A “second Window of Protection” Or Delayed Preconditioning 
Phenomenon: Future Horizons for Myocardial Protection? Journal of Molecular and Cellular 
Cardiology,27(4). :1023-1034. 
Yellon, D.M. & Hausenloy, D.J. 2007. Myocardial Reperfusion Injury. New England Journal of 
Medicine, 357(11). :1121-1135. 
Yu, H., Littlewood, T. & Bennett, M. 2015. Akt Isoforms in Vascular Disease. Vascular 
pharmacology 
Yurtcu, N., Cetin, A., Karadas, B., et al. 2006. Comparison of Effects of Formoterol and BRL 37344 
on Isolated Term-Pregnant Rat Myometrial Strips in Vitro. European journal of 
pharmacology, 530(3). :263-269. 
Zhang, Q.  Xiang, J., Wang, X., et al. 2010. Β2‐adrenoceptor Agonist Clenbuterol Reduces Infarct 
Size and Myocardial Apoptosis After Myocardial ischaemia/reperfusion in Anaesthetized 
Rats. British journal of pharmacology,160(6). :1561-1572. 
Zhang, Z., Ding, L., Jin, Z., et al. 2014. Nebivolol Protects Against Myocardial Infarction Injury Via 
Stimulation of Beta 3-Adrenergic Receptors and Nitric Oxide Signaling. PloS one, 9(5). :e98179. 
Zhang, Y., Lee, TS., Kolb, EM., et al 2006. AMP-Activated Protein Kinase is Involved in Endothelial 
NO Synthase Activation in Response to Shear Stress. Arteriosclerosis, Thrombosis, and 
Vascular Biology, 26(6). :1281-1287. 
Stellenbosch University  https://scholar.sun.ac.za
92 
 
Zhao, Z.Q. Corvera, JS., Halkos, ME., et al 2003. Inhibition of Myocardial Injury by Ischemic 
Postconditioning during Reperfusion: Comparison with Ischemic Preconditioning. American 
journal of physiology.Heart and circulatory physiology, 285(2). :H579-88. 
Zheng, M., Zhu, W., Han, Q. & Xiao, R. 2005. Emerging Concepts and Therapeutic Implications of β-
Adrenergic Receptor Subtype Signaling. Pharmacology & therapeutics, 108(3). :257-268. 
Zheng, M., Han, Q.D. & Xiao, R.P. 2004. Distinct Beta-Adrenergic Receptor Subtype Signaling in the 
Heart and their Pathophysiological Relevance. Sheng li xue bao : [Acta physiologica 
Sinica], 56(1). :1-15. 
Zhu, S., Liu, Y., Zhu, Y., et al. 2013. Remote Preconditioning, Perconditioning, and Postconditioning: 
A Comparative Study of their Cardio-Protective Properties in Rat Models. Clinics, 68(2). :263-
268. 
 
 
 
 
 
 
 
 
Stellenbosch University  https://scholar.sun.ac.za
